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1 
INTRODUCTION 
 
Inflammation 
Inflammation is a normal, essential, and protective response to any noxious 
stimulus that may threaten the host and may vary from a localized reaction to a 
complex response involving the whole organism. 
 
Many substances called mediators are formed or realized either concurrently 
or in successive time sequences at the site of injury. Various cell sources are 
responsible to an etiological factor. Various cells containing potent mediators and in 
some instances, inhibitors of the inflammatory response. These cell sources may 
include neutrophils, basophils, mast cells, platelets, macrophages and lymphocytes. 
The mediators of inflammation implicated in the inflammatory process and elaborated 
by the foregoing cells include histamine, serotonin, plasmakinins, lymphokines and 
prostaglandins (1) Davis and Granner, 1996) the process of inflammation can be 
summarized as follows. 
 
  Initial injury to tissues causing release of mediators, histamine, serotonin, 
prostaglandins. 
  An acute transient phase characterized by local vasodilatation and increased 
capillary permeability. 
  A delayed sub acute phase, most prominently characterized by infiltration of 
leukocytes and phagocytic cells. 
  A chronic proliferative phase, in which tissue degeneration and fibrosis 
occurs. 
 
Conditions of inflammation 
Many of the world’s major diseases like infection, cancer, autoimmunity and 
allergy, critically involve the inflammation. Continued progress in understanding 
basic mechanisms of inflammation is essential for developing new abilities to treat 
and prevent diseases that affect millions worldwide. 
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Rheumatoid arthritis (RA) 
Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease, 
the pathology of which is primarily and symmetrically localized in diarthrodial joints. 
The pathogenesis of RA is characterized by an inflamed synovium (lining the joint 
cavity), degradation of articular cartilage and erosion of sub-chondral bone. The 
systemic ramifications of the disease, with their attendant morbidity and mortality, 
include cardiopathy, nephropathy, vasculopathy and pulmonary and cutaneous 
disorders (2)Firestein., 2001). The prevalence of RA in India is quite similar to that 
reported from the developed countries. Projected to the whole population, this would 
give a total of about seven million patients in India. It is higher than that reported 
from China, Indonesia, Philippines and rural Africa. (3)Malaviya et al., 1993). 
Although the cause of RA is unknown, the presentation of anarthritogenic self antigen 
to a genetically susceptible individual is believed to trigger the activation of auto-
immunological pathways that lead to RA. Intense investigation of the cause of RA has 
uncovered many of the integral biochemical, cellular and molecular  pathological 
components and pathways of this disease, leading to the discovery, development and 
marketing of new and novel therapeutics that target several seminal components of 
RA (2)Firestein, 2001). Thus, arthritis is an autoimmune disease in which 
inflammation is a predominant feature. Inflammation is the reactive state of 
hyperemia and exudation from blood vessels with consequent redness, heat, swelling 
and pain which a tissue manifests in response to physical or chemical injury or 
bacterial invasion. The present investigation was designed to unravel the analgesic, 
anti-inflammatory & antiarthritic activity hydroalcoholic extract of Plumbago 
zeylanica in various animal models. 
 
Inflammation: 
Inflammation is nature’s double-edged sword. Inflammation characterized by 
pain and swelling, is triggered as a healing response in the body when it is injured or 
attacked by negative bacteria and viruses. Once the body recovers, the inflammation 
goes away. Obviously, dark side of inflammation, inflammation that doesn’t heal, that 
doesn’t go away, is one of the most prevalent health problems today. Dangers of 
Conventional Treatment for Inflammation 
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  Inflammation is the complex biological response of vascular tissues to harmful 
stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the 
organism to remove the injurious stimuli as well as initiate the healing process for the 
tissue. Inflammation is not a synonym for infection. Even in cases where inflammation 
is caused by infection it is incorrect to use the terms as synonyms: infection is caused 
by an exogenous pathogen, while inflammation is the response of the organism to the 
pathogen. 
 
  In pathologic conditions such as non-healing pressure ulcers, this efficient and 
orderly process is lost and the ulcers are locked into a state of chronic inflammation 
characterized by abundant neutrophil infiltration with associated reactive oxygen 
species and destructive enzymes. Healing proceeds only after the inflammation is 
controlled. On the opposite end of the spectrum, fibrosis is characterized by excessive 
matrix deposition and reduced remodeling. Often fibrotic lesions are associated with 
increased densities of mast cells. By understanding the functional relationships of these 
biological processes of normal compared to abnormal wound healing, hopefully new 
strategies can be designed to treat the pathological conditions. 
Comparison between acute and chronic inflammation: 
 Acute Chronic 
Causative agent 
Pathogens, injured 
tissues 
Persistent acute inflammation due to 
non-degradable pathogens, persistent 
foreign bodies, or autoimmune 
reactions 
Major cells involved 
Neutrophils, 
mononuclear cells 
(monocytes, 
macrophages) 
Mononuclear cells (monocytes, 
macrophages, lymphocytes, plasma 
cells), fibroblasts 
Primary mediators 
Vasoactive amines, 
eicosanoids 
IFN-γ and other cytokines, growth 
factors, reactive oxygen species, 
hydrolytic enzymes 
Onset Immediate Delayed 
Duration Few days Up to many months, or years 
Outcomes 
Healing, abscess 
formation, chronic 
inflammation 
Tissue destruction, fibrosis 
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The characteristics of inflammation can be divided into acute, chronic, 
irritability and immunity related inflammation. Any factor that induces tissue damage 
could be described as the pathogenesis of an inflammation. There are two kinds of 
induced inflammation factors: the inflammation stimulation factors, which mainly 
include physical (e.g., bruises, burns, frostbite, radial damage, etc.) and chemical 
factors (acid, alkali, allergens, mineral oil, etc.), and biochemical factors 
(microorganisms, parasites, endotoxins, transplant heterogeneity and animal toxins). 
Other inflammatory media include histamine, bradykinin, prostaglandin, platelet 
activation factor, neutrophils hydrolase, inflammation prestimulation factors (TNF, 
IL-1, IL-6, cell chemotaxis factor, etc.), adherence cell (select element, conformity 
element, adherence cell between cells, blood vessel cell adherence cell, etc.), cruor 
system stimulation factor, acute reaction protein (C reaction protein, LPS combined 
protein, serum starched protein A, etc.) (4)Akarasereenont et al., 1995). So 
inflammation is nature’s double-edged sword. 
 
Causes of Inflammation 
Various agents may kill or damage cells as: Physical (heat or cold, Trauma, 
radiation), chemical (simple chemical poisons e.g.: acid, organic poisons e.g.: 
paraquat), Infection (bacteria, virus), Immunological (antigen – antibody, cell 
mediated) 
 
Pathology of Inflammation 
The classical signs of inflammation are: Redness (Rubor), Swelling (Tumor), 
Heat (color), Pain (Dolor), Loss of Function. 
 
Distinct phases of inflammatory responses 
 First phase is caused by an increase in vascular permeability resulting in 
exudation of fluids from the blood into the interstitial space. 
 The second phase involves the infiltration of leukocytes from the blood into 
the tissue. 
 Granuloma formation and tissue repair. 
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Distinct phases of inflammatory response 
Vasodilatation and increased permeability of blood vessels 
Within minutes after an injury, dilatation of arterioles and increased 
permeability of capillaries produce heat, redness and swelling in the affected area. 
The large amount of warm blood flowing through the area produces both heat and 
redness. Edema results from increased permeability of blood vessels, which permits 
more fluid to move from blood into tissue spaces, pain whether immediate or delayed 
is cardinal symptom of inflammation; it can result from injury of nerve fibres or from 
irritation by toxic chemicals from micro-organisms. Kinins affect some nerve endings 
causing much of the pain associated with inflammation. 
 
Exudation of leukocytes 
Changes in the formed elements of blood 
In the early stage of inflammation, the rate of flow of blood is increased due to 
vasodilatation. But subsequently, there is slowing or stasis of blood stream. With 
stasis, changes in the normal axial flow of blood in the microcirculation take place. 
Due to slowing and stasis, the central stream of cells widens and peripheral plasma 
zone becomes narrower because of loss of plasma by exudation. This phenomenon is 
known as margination. As a result of this redistribution, the neutrophils of the central 
column come close to the vessel wall, this is known as pavementing. 
 
Adhesion 
In this, peripherally marginated and pavemented neutrophils stick briefly to 
the endothelial cells lining the vessel wall or roll over it. 
 
Emigration 
After sticking of neutrophils to endothelium, they begin to squeeze through the 
wall of the blood vessel to reach the damaged area. This process is known as 
emigration. Simultaneous to emigration of leukocytes, escape of red cells through 
gaps between the endothelial cells, diapedesis takes place. 
 
Introduction 
 
 
6 
Chemotaxis 
The chemotactic factor mediated transmigration of leukocytes after crossing 
several barriers to reach the interstitial tissues is called chemotaxis. 
 
Phagocytosis 
Phagocytosis is defined as the process of engulfment of solid particulate 
material by the cells. There are 2 main types of phagocytosis cells. 
 Polymorphonuclear neutrophils 
 Macrophages 
 
Phagocytosis involves the following 4 steps: 
1. Attachment stage 
2. Engulfment stage 
3. Secretion stage 
4. Killing stage 
 
Mediators of inflammation 
 
Plasma derived mediators: 
Name Produced by Description 
Bradykinin Kinin system 
A vasoactive protein which is able to induce 
vasodilation, increase vascular permeability, cause 
smooth muscle contraction, and induce pain. 
C3 
Complement 
system 
Cleaves to produce C3a and C3b. C3a stimulates 
histamine release by mast cells, thereby producing 
vasodilation. C3b is able to bind to bacterial cell walls 
and act as an opsonin, which marks the invader as a 
target for phagocytosis. 
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C5a 
Complement 
system 
Stimulates histamine release by mast cells, thereby 
producing vasodilation. It is also able to act as a 
chemoattractant to direct cells via chemotaxis to the 
site of inflammation. 
Factor - XII 
(Hageman 
Factor) 
Liver 
A protein which circulates inactively, until activated by 
collagen, platelets, or exposed basement membranes 
via conformational change. When activated, it in turn is 
able to activate three plasma systems involved in 
inflammation: the kinin system, fibrinolysis system, 
and coagulation system. 
Membrane 
attack 
complex 
Complement 
system 
A complex of the complement proteins C5b, C6, C7, 
C8, and multiple units of C9. The combination and 
activation of this range of complement proteins forms 
the membrane attack complex, which is able to insert 
into bacterial cell walls and causes cell lysis with 
ensuing death. 
Plasmin 
Fibrinolysis 
system 
Able to break down fibrin clots, cleave complement 
protein C3, and activate Factor XII. 
Thrombin 
Coagulation 
system 
Cleaves the soluble plasma protein fibrinogen to 
produce insoluble fibrin, which aggregates to form a 
blood clot. Thrombin can also bind to cells via the 
PAR1 receptor to trigger several other inflammatory 
responses, such as production of chemokines and nitric 
oxide. 
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Cell derived mediators: 
Name Type Source Description 
Lysosome 
granules 
Enzymes Granulocytes 
These cells contain a large variety of 
enzymes which perform a number of 
functions. Granules can be classified 
as either specific or azurophilic 
depending upon the contents, and are 
able to break down a number of 
substances, some of which may be 
plasma-derived proteins which allow 
these enzymes to act as inflammatory 
mediators. 
Histamine 
Vasoactive 
amine 
Mast cells, 
basophils, 
platelets 
Stored in preformed granules, 
histamine is released in response to a 
number of stimuli. It causes arteriole 
dilation and increased venous 
permeability. 
IFN-γ Cytokine 
T-cells, NK 
cells 
Antiviral, immunoregulatory, and 
anti-tumour properties. This 
interferon was originally called 
macrophage-activating factor, and is 
especially important in the 
maintenance of chronic inflammation. 
IL-8 Chemokine 
Primarily 
macrophages 
Activation and chemoattraction of 
neutrophils, with a weak effect on 
monocytes and eosinophils. 
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Leukotriene B4 Eicosanoid Leukocytes 
Able to mediate leukocyte adhesion 
and activation, allowing them to bind 
to the endothelium and migrate across 
it. In neutrophils, it is also a potent 
chemoattractant, and is able to induce 
the formation of reactive oxygen 
species and the release of lysosome 
enzymes by these cells. 
Nitric oxide Soluble gas 
Macrophages, 
endothelial 
cells, some 
neurons 
Potent vasodilator, relaxes smooth 
muscle, reduces platelet aggregation, 
aids in leukocyte recruitment, direct 
antimicrobial activity in high 
concentrations. 
Prostaglandins Eicosanoid Mast cells 
A group of lipids which can cause 
vasodilation, fever, and pain. 
TNF-α and IL-1 Cytokines 
Primarily 
macrophages 
Both affect a wide variety of cells to 
induce many similar inflammatory 
reactions: fever, production of 
cytokines, endothelial gene 
regulation, chemotaxis, leukocyte 
adherence, activation of fibroblasts. 
Responsible for the systemic effects 
of inflammation, such as loss of 
appetite and increased heart rate. 
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Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease of 
the joints but may affect other organ systems. (5)Douglas et al 2001). RA is 
characterized by Synovial proliferation as well as inflammatory and immunological 
processes. These mechanisms lead to largely irreversible degradative and erosive 
changes in the articular cartilage and juxtaarticular bone, and to a systemic 
disturbance of bone remodeling, finally resulting in systemic osteopenia. Initially, RA 
most commonly affects the small joints of the hand and wrist in a symmetrical 
fashion, and it has a predilection for the metacarpophalangeal (MCP) and proximal 
interphalangeal (PIP) joints in the first instance. The distal interphalangeal (DIP) 
joints are spared in the vast majority of cases. It may occasionally present, however, 
as a monoarthritis of a large joint, such as the knee or shoulder. It is an autoimmune 
disease, which is defined clinically by the pattern of joint involvement and synovial 
swelling which is often described as ‘boggy’ due to the inflammatory nature of the 
synovial pathology. It may also be associated with the presence of circulating 
rheumatoid factor in the serum in 85% of patients, this is most commonly an IgM 
antibody directed against an IgG molecule. The test for rheumatoid factor is of some 
diagnostic use. However as it is not always present, especially in early disease, RA 
should not be excluded on the basis of a negative test. The rheumatoid hand is 
therefore critical in the assessment of patients suspected of early or recent onset RA. 
If we are to prevent joint damage, limit deformity and thereby preserve function it is 
imperative to identify the ‘rheumatoid hand’ before it develops the well described 
characteristic anatomical changes of longstanding disease. These changes include 
boutonniere or swan-neck deformities, ulnar deviation of the fingers and subluxation 
of the MCP and wrist joints. 
 
In recent years, algorithms have been developed to identify individuals at high 
risk of RA, based on clinical features such as gender, family history and laboratory 
investigations such as C reactive protein, rheumatoid factor and even genetic typing 
using the shared epitope. It has been demonstrated that the third hypervariable region 
of the HLA DR4molecule is associated with RA, although it remains unclear whether 
it is a marker for susceptibility or severity. Recent studies show that clinical 
examination of the rheumatoid hand is relatively poor at detecting low grade or early 
Introduction 
 
 
11 
synovitis and therefore more sensitive diagnostic methods are needed. Diagnostic 
approaches in early disease have been under intense focus in the last10 years as rapid 
technological development of imaging techniques such as high resolution ultrasound 
(HRUS) and magnetic resonance imaging (MRI) offer specific advantages over 
conventional techniques. Therapeutic strategies have also changed rapidly over the 
past 20 years, and most recently have been transformed with the introduction of 
combination therapeutic approaches and the development of biologic agents. (5) 
Douglas et al 2001). 
 
The therapeutic approach affords symptomatic relief but the process of 
degeneration of the cartilage is not arrested by the drugs like NSAIDS. There is 
paucity of disease modifying drugs. However in the traditional system of medicine 
large no of plants have been reported to afford relief in the symptoms of rheumatoid 
arthritis. The polyphenols from plants are now investigated due to their antioxidant 
properties for Antiarthritic activity. 
 
Rheumatoid arthritis (RA), one of the commonest autoimmune diseases, is a 
chronic, progressive, systemic inflammatory disorder affecting the synovial joints and 
typically producing symmetrical arthritis that leads to joint destruction, which is 
responsible for the deformity and disability. The consequent morbidity and mortality 
has a substantial socio-economic impact. Epidemiology of the arthritis in female:male 
is 3:1 and the prevalence is 1% of the world population. (6)Narendhirakannan et al 
2007). In human as well as in animal models, RA is characterized by a series of 
pathological processes of the joints, such as leukocyte infiltration, a chronic 
inflammation, pannus formation, and extensive destruction of the articular cartilage 
and bone. Although the exact cause of RA has not been elucidated in detail, pro- and 
anti-inflammatory cytokines seem to play an important role in the etiology of the 
disease. In particular, it was reported that the inflammatory cytokines, such as tumor 
necrosis factor (TNF)-α, interleukin (IL)- 1β, and IL-6, play key roles in the 
inflammation and joint damages during the development of RA (7)Yeom et al 2006) 
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ETIOLOGY 
The cause of RA is thought to be a mixed result of genetic and environmental 
factors. Genetics determines about 50% to 60% of the susceptibility severity, and 
phenotypes for RA Monozygotic twins have concordance rates of 15%, while 
dizygotic rates fall around 4%. The association with HLA locus types has been well 
studied.  Recently, a shared epitope within the third hypervariable region of 
HLADRB1 *0401 and *0404 alleles was reported to indicate more susceptibility and 
more severe disease. Susceptibility and severity are greater in men younger than 30 
years with this genotype, even though young men as a whole have a reduced risk of 
RA. Homozygote’s for these alleles are at an increased risk of severe disease, 
especially in younger men. However, showed an almost equivalent RA risk in men 
and women homozygous for the shared epitope . The risk for RA increases with more 
shared epitope involvement. 80% have at least 1 shared epitope and 42% have 2. The 
strongest association is seen with the *0401/0404 genotype. The combination of male 
gender and having 1 or 2 shared epitopes correlates directly with worse outcome. 
Shared epitope disease is associated with a younger age of onset, more joint 
tenderness, swelling, deformity, and RF positivity.HLA-DRw3 appears to be 
associated with greater RF positivity, rheumatoid nodules, and overall disease 
severity. HLA-DRw4 is linked to a family history of disease (77% versus 34% in 
control subjects). HLA-DRw3 and -DRw2 genotypes have also been shown to 
increase the chance of toxic reactions to RA therapy. HLA-DRw2 allele, however, 
appears to be a protective factor; it is seen less in RA patients and its presence is 
associated with fewer rheumatoid nodules and lower RF titers in patients. Non-HLA 
based genetic associations, especially on chromosomes 1p, 1q, and 18q, is also noted 
and are based on a combined analysis of 512 multicase families. Nongenetic 
components include aging, acquired genomic variability, possible bacterial or viral 
triggers, and other environmental factors. Smoking is the only lifestyle factor 
determined to be related to RA development. Aging is a risk factor for RA, as age-
adjusted incidence per 100,000 persons is greatest among persons between 60 and 65 
years of age. The illness may be associated with Epstein- Barr virus and Escherichia 
coli infections, since they have cross-reactive molecular links to the hypervariable 
domains of HLA DRDw4 and HLA-DRB1 seen in RA patients, (8)Sayah et al 2005) 
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PATHOGENESIS  
RA appears to develop from a deregulated immune response that leads to 
progressive synovial inflammation and joint destruction. Heretofore, precipitating 
factors for the development of RA have not been elucidated fully, though T-cell 
involvement has been strongly implicated. CD4 T cells characteristically are 
infiltrating the synovium, a finding that suggests the process is mediated by T cells. 
Cytokines, primarily interleukin-1andtumornecrosis factor-a, and, recently reported, 
activation-induced, T-cell derived, chemokine-related cytokine/lymphotactin and 
macrophage migration inhibitory factor have been found in high levels in RA patients. 
These endogenous compounds stimulate synovial tissue effector functions, including 
proliferation, metalloproteinase expression, adhesion-molecular expression, secretion 
of other cytokines, and prostaglandin production—all of which may have a role in RA 
pathogenesis. Matrix metalloproteinase cause cartilage and bone degradation by 
means of extracellular matrix remodeling and degradation. Aberrant adhesion 
molecule expression leads to uncontrolled binding of T cell synovial type B cells, 
resulting in excess release of matrix metalloproteinase’s. Other possible actors include 
neoangiogenesis, cyclo-oxygenases, nitric oxide synthase, and neutral proteases.4 RF 
is a group of auto antibodies (IgM, IgG, and IgA) that recognizes the Fc portion of 
IgG. It can be found in healthy persons during an immune response and in patients 
with various autoimmune diseases, as well as in those with chronic bacterial 
infections. Normally RF aids in the clearing of immune complexes, the processing of 
antigens by B cells, and the development of an early antibody repertoire. Increases in 
RF production commonly are seen prior to the clinical onset of RA. Various theories 
exist as to the origin of RF. They include triggering by IgG-antigenebased immune 
complexes, foreign antigen or autoantigen cross reactivity, anti-idiotype mimicry of 
exogenous Fc binding proteins (such as Staphylococcus aureus protein A), polyclonal 
B-cell activation by infections, and Fc glycosylation changes. There also appears to be 
a class switch from IgM to IgG, making it more pathologic. The antigen that triggers 
T-helper cells to aid in the switch is yet unknown. Although high levels of both IgM 
and IgG correlate with RA activity, increases in IgM and IgA together have been 
shown to have a strong specificity and predictive value for RA. These antibodies are 
heterogeneous and appear to change forms throughout the disease course, 
progressively increasing affinity for the Fc region. Pathogenic RF differs from that 
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seen in healthy persons in isotope, specificity, mutation frequency, and the ability to 
activate complement. The complete role of RF in RA pathogenesis is unclear. One 
part of the autoimmune response to RA may be due to the development of RF 
complexes. These complexes fix complement, recruit macrophages, neutrophils, and 
lymphocytes, and release cytokines upon ligation of Fc-gamma receptors on 
macrophages that together lead to inflammation. There is also a correlation between 
RF at baseline and future bone erosions. Specifically, IgA RF may lead to excessive 
intra-articular tissue growth factor-b secretion, creating the bone erosions seen in RA. 
As a marker of disease, RF correlates well with C-reactive protein but not erythrocyte 
sedimentation rate (ESR). Titers also correlate with arthritis severity and joint 
destruction, as well as vasculitis. (8)Sayah et al 2005) 
 
TREATMENT 
 
DESIRED OUTCOME; 
The primary objective is to improve or maintain functional status there by 
improving quality of life. Treatment of rheumatoid arthritis is a multifaceted approach 
that includes pharmacologic and nonpharmacologic therapies. Recent emphasis has 
been placed on aggressive treatment early in the disease course. The ultimate goal is 
to achieve complete disease remission, although this goal is seldom achieved. 
Additional goals of treatment include controlling disease activity and joint pain, 
maintaining the ability to function in daily activities or work, improving the quality of 
life, and slowing destructive joint changes. (9)Dipiro et al 2005) 
 
NONPHARMACOLOGIC THERAPY; 
3  Rest, occupational therapy, physical therapy, use of assistive devices, weight 
reduction, and surgery are the most useful types of nonpharmacologic therapy used in 
patients with rheumatoid arthritis. Rest is an essential component of a 
nonpharmacologic treatment plan. It relieves stress on inflamed joints and prevents 
further joint destruction. Rest also aids in alleviation of pain. Too much rest and 
immobility, however, may lead to decreased range of motion, and ultimately muscle 
atrophy and contractures. Occupational and physical therapy can provide the patient 
with skills and exercises necessary to increase or maintain mobility. These disciplines 
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also may provide patients with supportive and adaptive devices such as canes, 
walkers, and splints. Other nonpharmacologic therapeutic options include weight loss 
and surgery. Weight reduction helps to alleviate stress on inflamed joints. This should 
be instituted and monitored with close supervision of a health care professional. 
Tenosynovectomy, tendon repair, and joint replacements are surgical options for 
patients with rheumatoid arthritis. Such management usually is reserved for patients 
with severe disease. (9)Dipiro et al 2005) 
 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
Because of their analgesic and anti-inflammatory properties, nonsteroidal anti-
inflammatory drugs (NSAlDs) are basic therapy for patients with RA. High doses and 
scheduled dosing may be required to achieve sufficient anti-inflammatory activity 
with NSAlDs in these patients. NSAlDs provide analgesia and suppress inflammation 
by inhibiting the enzyme cyclooxygenase (COX), resulting in decreased prostaglandin 
synthesis. The suppression of prostaglandin synthesis can also produce gastric and 
renal toxicity, as well as impair normal platelet function.COX exists in 2 isoenzymatic 
forms, COX-1 and COX-2. COX-1 is constitutively expressed in many types of tissue 
and produces prostaglandins that regulate normal cellular functions. However, COX-2 
activity is induced by inflammatory cytokines to produce prostaglandins that mediate 
the inflammatory response. Traditional nonspecific NSAlDs inhibit both COX-1 and 
COX-2, and in doing so, not only decrease inflammation and pain but also promote 
gastrointestinal tract damage and bleeding. Therefore, development of a new class of 
anti-inflammatory drugs that primarily inhibit COX-2 while sparing the enzymatic 
activity of COX-1 at therapeutic doses may offer increased safety for long-term use of 
NSAlDs in chronic inflammatory diseases such as RA. Celecoxib, a novel NSAlD 
that selectivly inhibits the enzyme COX-2, is now approved by the US Food and Drug 
Administration (FDA) for treatment of RA and osteoarthritis (OA). In active RA, 
treatment with celecoxib 100 to 400 mg twice daily and naproxen 500 mg twice daily 
achieved significant reductions in pain, morning stiffness, and tender/swollen joints. 
In patients with stable RA, celecoxib 200 mg twice daily showed sustained 
symptomatic improvements similar to those of twice-daily slow-release diclofenac 75 
mg over a 24week period. In patients with OA of the knee, celecoxib 100 and 200 mg 
once and twice daily had efficacy superior to placebo and comparable to naproxen 
500 mg twice daily. Celecoxib has been further indicated in patients with familial 
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adenomatous polyposis and/or colon cancer. It is postulated that NSAlDs may act to 
retard, block, or reverse colonic carcinogenesis, and celecoxib, being a COX-2 
inhibitor, has the advantage of causing minimal gastrointestinal adverse effects.12 
The common adverse effects reported with celecoxib are nausea, diarrhea, and 
abdominal pain. The incidence of upper gastrointestinal ulcer complications was 
eightfold lower with celecoxib than with nonspecific NSAIDs, but similar to that in 
patients taking placebo.Thus, the gastrointestinal tolerability of celecoxib is much 
better than that of traditional NSAIDS. 
  
Pharmacokinetic studies of celecoxib in healthy subjects showed that peak 
blood concentrations occur 3 hours after oral administration. A high-fat meal delayed 
intestinal absorption of celecoxib but increased its bioavailability by -40%. Celecoxib 
is highly bound to plasma proteins (97%) and its volume of distribution is -400 L. The 
drug is metabolized predominantly in the liver via cytochrome P450 2C9, and 3% of 
celecoxib is excreted unchanged in urine and feces. Therefore, the drug may 
accumulate in the body in patients with moderate hepatic impairment but not in 
patients with chronic renal failure. However, elimination of the drug in patients with 
severe renal insufficiency has not yet been investigated. Interactions between 
celecoxib and other concomitantly administered drugs have been investigated. 
Fluconazole, a hepatic microsomal enzyme inhibitor, may cause elevation of plasma 
concentration of celecoxib up to twofold. Celecoxib 200 mg/d may raise the plasma 
concentration of lithium administered at a dosage of 450 mg twice daily if the 2 drugs 
are given together.” Concomitant administration of warfarin and celecoxib in healthy 
volunteers showed no significant effect on prothrombin time or steady-state 
pharmacokinetics of S- or R-warfarin.  
 
Rofecoxib is another novel drug with a specific inhibitory effect on COX-2. It 
was approved by the FDA in May 1999 for the treatment of OA, primary 
dysmenorrhea, and acute pain in adults but has not yet received FDA approval for 
RA. Treatment with rofecoxib 12.5 to 25 mg/d has been found to be well tolerated. 
The most frequent adverse effects reported for the drug are upper respiratory tract 
infection, diarrhea, nausea, headache, insomnia, and edema. All the adverse effects 
were transient, and none required patients to discontinue therapy. Furthermore, the 
occurrence of gastrointestinal ulcers as common complications of traditional NSAID 
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therapy has been significantly reduced with rofecoxib administration to a level 
comparable to that of placebo. Pharmacokinetic studies showed no effect of fatty 
meals on the oral bioavailability of rofecoxib. Plasma protein binding was 87%. The 
drug is predominantly metabolized in the liver by cytosolic enzymatic reduction, with 
hepatic cytochrome P450 having a minor role. Renal elimination of rofecoxib is cl%, 
and its elimination half-life is 17 hours. The drug is not recommended for use in 
patients with hepatic impairment, and safety information about its use in patients with 
advanced renal disease is still lacking. Interactions have been reported between 
rofecoxib and other drugs given concomitantly. Coadministration of rofecoxib and 
angiotensin-converting enzyme inhibitors may cause elevation in mean arterial 
pressure by 3 mm Hg. 
 
The plasma concentration of either methotrexate (MTX) or lithium may 
increase when rofecoxib is coadministered. The prothrombin time was increased 
when rofecoxib was given concomitantly with warfarin. Administration of rifampin 
decreased the plasma concentration of rofecoxib by 50%.22 From the 
pharmacoeconomic point of view, the use of COX-2 inhibitors would seem to be cost-
effective, since the incidence of gastrointestinal adverse events, especially bleeding 
and ulcers, is reduced with these drugs. However, in a l-year assessment of the cost-
effectiveness potential of COX-2 inhibitors, the reduction in gastrointestinal adverse 
effects did not translate into economic benefit, and more long-term studies are needed. 
It is encouraging that anti-inflammatory drugs such as celecoxib and rofecoxib do not 
have many of the side effects of glucocorticoids and traditional NSAIDs. While their 
long-term safety is being established by pharmacovigilance studies, they could be 
prescribed in the at-risk population or for other indications (eg, preterm labor, 
colorectal cancer). However, further investigations are needed to solve the following 
therapeutic problems: (1) whether these drugs are therapeutically effective at doses 
that affect only the desired enzymeisoforms; (2) whether near-complete inhibition of 
COX-2 is safe, especially if sustained for prolonged periods; (3) whether inhibition of 
COX-2 will prove adequate for interrupting the inflammatory response in the setting 
of entirely intact COX-l-dependent prostanoid production; and (4) what the long-term 
effects of COX-2 inhibition will be on renal function. (Ehab .2001) 
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DISEASE-MODIFYING ANTIRHEUMATIC DRUGS 
The disease-modifying antirheumatic drugs (DMARDs) are not a new concept 
in the treatment of RA; several of these drugs are currently available. They include 
MTX, sulfasalazine (SSZ), hydroxychloroquine (HCQ), cyclosporine, gold salts, 
penicillamine, and azathioprine. These agents are expected to slow radiologically 
identifiable signs of disease progression in RA, but their long-term impact on 
disability has yet to be proven. It has been reported that early, combined therapy with 
DMARDs is more beneficial and less hazardous than late monotherapy in patients 
with RA. (Ehab 2001) 
 
Methotrexate 
The folic acid antagonist MTX is increasingly regarded as the agent of first 
choice in the treatment of RA because of its early onset of action and superior 
efficacy and tolerability. It is usually given orally at a dosage of 7.5 to 15 mg once 
weekly. Since the bioavailability of oral MTX is reduced with doses >20 mg, the drug 
is administered intramuscularly in that dosing range. Clinical response to MTX in RA 
is often observed 2 to 3 weeks from initiation of therapy, and -50% to 67% of patients 
continue long-term therapy with MTX.2 Gastrointestinal upset, elevation of liver 
enzymes, and hemocytopenia are adverse effects of MTX that may lead to treatment 
discontinuation. Folic acid administration in doses of 1 to 10 mg/d during therapy 
with MTX may reduce the gastrointestinal adverse effects of MTX without interfering 
with its efficacy. Pneumonitis is a rare side effect of long-term therapy with MTX. Its 
incidence may be higher in RA patients who are aged ~65 years and have interstitial 
lung disease.The adverse effects of MTX are usually observed in the first year of 
treatment; extended follow-up revealed no clinically detectable cumulative toxicity 
over a 5-year period. The efficacy of MTX when given weekly in small doses in RA 
is not related to the plasma concentration of the drug. It is suggested that MTX 
reduces the concentration of circulating purines and pyrimidines, consequently 
decreasing their availability for DNA and RNA synthesis. This may affect 
proliferation of immune cells and expression of cytokines. 
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Antibiotics 
An infectious etiology of RA has long been postulated but has not been 
proved. Despite insufficient evidence for the infectious nature of this disorder, several 
antibacterial agents, such as sulfa compounds (e.g, SSZ) and tetracyclines 
(eg,minocycline) have been shown to be efficacious in the treatment of RA. SSZ is 
most commonly used in Europe to treat RA. The drug combines an anti-inflammatory 
agent (5aminosalicylic acid) and a sulfa antibiotic (sulfapyridine). The latter 
component is the active metabolite of the drug. The mechanism of action of SSZ 
against RA is unknown. It is possible that SSZ causes alteration in the intestinal flora 
of RA patients. Furthermore, the drug has immunologic effects in RA.  SSZ is given 
initially at a dosage of 500 mg once or twice daily, and the dosage is gradually 
increased over several months to 2 to 3 g/d. This dosage regimen improves the gastric 
tolerance to SSZ and reduces the gastrointestinal adverse effects that may lead to drug 
discontinuation. Neutropenia and thrombocytopenia may occur in 10% to 25% of 
cases and become serious in 2% to 5% of cases. These toxicities are most likely to 
occur in the first 6 months of therapy; therefore, complete blood count should be 
monitored periodically. Minocycline 200 mg/d has been used in the treatment of RA. 
Recent studies demonstrated a beneficial effect of the drug in both early and advanced 
stages of the disease. Among patients with seropositive RA, remissions are more 
frequent and the need for DMARD therapy is less in those treated early in the disease 
with minocycline compared with patients given conventional therapy delayed by an 
average of only 3 months. Therefore, minocycline may be beneficial in patients with 
RA, especially when given early in the disease course or in patients with mild 
disease.In RA, minocycline may suppress T-cell activity (immunomodulatory) and 
inhibit metalloprotease enzymes (antiinflammatory). Both are necessary to mediate 
joint destruction. Dizziness is the most commonly reported side effect during 
minocycline therapy. Other side effects include gastrointestinal upset, rash, 
pneumonitis, and headache. Minocycline appears promising as a DMARD, but its use 
is limited by the lack of comparative studies. 
 
Hydroxychloroquine 
The antimalarial drug HCQ has been prescribed for the treatment of RA. It is 
usually given at 400 mg/d, but its delayed onset of action in RA (3 to 6 months) has 
led to the suggestion of a higher initial dosage to accelerate the clinical response. A 
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loading dosage of either 800 mg/d or 1200 mg/d for 6 weeks followed by a 
maintenance dosage of 400 mg/d has been found to hasten the response to HCQ. 
Unlike many other DMARDs, HCQ is not associated with renal, hepatic, or bone 
marrow toxicity in patients with RA. However, patients may discontinue the drug 
because of the most frequent gastrointestinal adverse effects (nausea, vomiting, and 
abdominal pain). Other side effects reported are rash, vertigo, headache and insomnia. 
The principal ocular adverse effect of HCQ is a progressive retinopathy involving 
color vision changes. This retinopathy has been noted to occur without early warning 
signs and, therefore, ophthalmologic examinations are mandatory before therapy is 
started and every 4 to 6 months thereafter. The high loading dosage of HCQ (800-
1200 mg/d) has not been associated with greater ocular toxicity than the conventional 
dosage (400 mg/d) commonly used in RA. Furthermore, the new dosage regimen for 
HCQ (up to 1200 mg/d for 6 weeks) is well tolerated, except for the gastrointestinal 
adverse events. 
 
Triple Therapy 
Triple therapy, a successful combination therapy for early treatment of RA, 
consists of concomitant administration of MTX, SSZ, and HCQ. Application of this 
combination has been favored and has increased substantially for 3 reasons. First, 
most of the DMARDs lose their efficacy over time. Second, rheumatologists are not 
content with minor improvements in their patients. Finally, recent data indicate that 
combination therapy in RA can be safe and still be more efficacious than 
monotherapy with a DMARD. Triple therapy is advocated early in the disease, 
especially in patients with partial response to any of the DMARDs, SSZ plus HCQ 
had efficacy similar to that of MTX alone in RA. However, triple therapy (MTX + 
SSZ + HCQ) achieved a substantially greater benefit in patients with RA. Therefore, 
MTX is considered a basic drug in the Triple therapy. The adverse effects of triple 
therapy include gastrointestinal intolerance, weight gain, and elevation of liver 
enzymes. However, these side effects may be better tolerated in patients who are 
responding well to the triple regimen, even if the dosage has been increased up to 22.5 
mg/wk (MTX) or 2 g/d (SSZ). Attempts to taper any of the 3 drugs in triple therapy 
may lead to disease flare. 
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Cyclosporine 
Cyclosporine is an immunosuppressive drug used as a DMARD in the 
treatment of RA. In RA patients with suboptimal response to MTX alone, addition of 
cyclosporine can be effective. The recommended dosage of cyclosporine in 
combination with MTX ranges between 2.5 and 3.5 mg/kg per day but should not 
exceed 5 mg/kg per day. The previously recommended dosage of 10 mg/kg per day 
was toxic to the kidney. Cyclosporine and MTX have complementary mechanisms of 
action in RA. Cyclosporine inhibits interleukin-2 (IL-2) production and T-cell 
activity, whereas MTX inhibits IL-1 production and the activity of macrophages and 
monocytes. Cyclosporine is poorly absorbed orally (bioavailability is 30%), and both 
bile flow and ingestion of food can affect its intestinal absorption. Therefore the 
conventional cyclosporine (cyclosporin A) has been formulated as a microemulsion to 
improve its oral bioavailability. In this new formulation, cyclosporine is incorporated 
into a microemulsion of surfactant, ethanol, and a lipophilic and hydrophilic solution. 
When given orally in the micro emulsion formulation, the absorption of cyclosporine 
was greatly increased and its pharmacokinetic profile became more predictable. The 
common side effects of cyclosporine therapy are hypertension and renal impairment. 
They may be reversed by reducing the dose of drug or discontinuing therapy. The 
immunomodulating effects of cyclosporine may increase the relative risk of 
malignancy.Therefore, cyclosporine is not recommended for patients with RA who 
have any of the following conditions: current or past malignancy, except basal cell 
carcinoma; uncontrolled hypertension; renal dysfunction; or abnormal increase in 
liver enzyme activity (22 times baseline values). Cyclosporine metabolism in the liver 
via the cytochrome P450 enzymes may cause interactions with other coadministered 
drugs. Ketoconazole, erythromytin, calcium antagonists, and H, antagonists may 
inhibit drug metabolism, thereby elevating its plasma concentration. On the other 
hand, anticoagulants and rifampin increase cyclosporine metabolism and reduce its 
plasma concentration.  
 
Gold Salts 
Gold salts may be used in RA patients who have evidence of erosive joint 
lesions or who are responding unfavorably to conservative treatment. Gold salts come 
in oral auranofin and intramuscular preparations (gold sodium thiomalate). The usual 
dosage of auranofin is 3 mg twice daily, whereas injectable gold is usually given as 25 
Introduction 
 
 
22 
to 50 mg weekly until the patient responds. Then, the interval between injections is 
gradually increased to 2 to 4 weeks, according to the patient’s response. The onset of 
action of gold in RA is usually between 2 and 6 months from the initiation of therapy. 
It has been reported that the addition of MTX orally at a dosage of 7.5 mg weekly to 
injectable gold (50 mg once weekly) for the first 6 months of treatment in patients 
with early RA is more beneficial than gold monotherapy. Periodic monitoring of urine 
for protein, as well as complete blood count and platelet count for decreases in 
marrow cell lines, is essential for early identification of renal or bone marrow 
toxicities that may be induced by gold administration. If protein urea is evident, 
treatment should be discontinued. Other side effects include diarrhea (auranofin) and 
skin rash and stomatitis (injectable gold). 
 
Penicillamine 
Penicillamine is a DMARD that is not used frequently in patients with RA 
because of the risk of autoimmune reactions such as systemic lupus erythematosus, 
polymyositis, myasthenia gravis, and Goodpasture’s syndrome. Other adverse effects 
include proteinuria, myelosuppression, stomatitis, and rash. The initial dosage of the 
drug is 125 to 250 mg/d (given on an empty stomach); the dosage is gradually 
increased to 500 to 750 mg/d over several months to reduce the likelihood of toxicity. 
Clinical response to the drug is not usually expected until several months after 
initiating therapy. Penicillamine may induce proteinuria and myelosuppression, 
necessitating regular monitoring of urine for protein, as well as complete blood count 
and platelet count. Because of the potential adverse effects of the drug, penicillamine 
has become a second line treatment for RA. 
 
Azathioprine 
The purine analogue azathioprine is used in severe cases of RA. It is usually 
given in the range of 1 to 2 mg/kg per day. However, the high risk for 
myelosuppression and opportunistic infection associated with azathioprine therapy 
limits its use in RA. Recently azathioprine therapy has been tried in patients with 
active refractory RA. It was administered as a single intravenous loading dose of 22.5 
to 36 mg/kg body weight followed by an oral maintenance dose of 1.7 to 2.5 mg/kg 
per day. Despite patient’s tolerance to this dosing regimen, the loading dose did not 
appear to enhance control of the disease sufficiently to warrant a controlled clinical 
trial of this regimen. 
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CORTICOSTEROIDS: 
Corticosteroids can provide effective symptomatic therapy in RA. Because of 
their multiple adverse effects, corticosteroids are now recommended in small oral 
doses (eg, prednisone 7.5 mg/d) that may retard progression of bone erosion in RA. 
Monthly pulses with high doses may hasten the response to initial DMARD therapy. 
Also, corticosteroids may be given chronically when the response to combination 
therapy with NSAlDs plus DMARDs is inadequate. Furthermore, short courses of 
corticosteroids may be used during acute disease flares to reduce 
inflammation.Compared to NSAlDs, prednisolone proved more efficacious in 
reducing joint tenderness and pain, whereas the difference in grip strength was 
insignificant. The immunomodulatory and anti-inflammatory effects of corticosteroids 
in RA may be achieved through multiple mechanisms. They may inhibit nuclear 
factor kappa B, a unique cellular transcription factor that is involved in autoimmune 
inflammatory reactions. Corticosteroids may also increase expression of anti-
inflammatory cytokines (eg, IL-4). 
 
Corticosteroids are associated with many adverse effects, including 
osteoporosis, hypertension, hyperglycemia, increased appetite, fluid retention, weight 
gain, central nervous system effects, cataracts, glaucoma, and progression of 
atherosclerosis.  
 
Corticosteroid-induced osteoporosis has presented a challenge to clinicians for 
many years. Bone loss during long-term corticosteroid therapy is mediated by 
inhibition of gonadal and adrenal steroid production leading to hypogonadism and a 
direct negative effect on calcium absorption and osteoblast function. Therefore, both 
prevention and treatment of corticosteroid-induced osteoporosis are feasible with 
bisphosphonates or hormones. Bisphosphonates are considered the first option and are 
especially recommended for patients who meet any of the following criteria and who 
also use prednisolone (or an equivalent drug)  7.5 mg/d ,a history of premature 
menopause or a low-trauma fracture; a family history of osteoporosis; immobility; 
low body weight; or low bone mineral density. In all these conditions, 
bisphosphonates are usually indicated, especially when the patients are unwilling to 
take hormone replacement therapy. Hormonal therapy may be indicated in 
postmenopausal women and in all men and premenopausal women with evidence of 
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hypogonadism. Hormone replacement therapy with sex steroids increases bone 
mineral density in the lumbar spine in patients with corticosteroid- induced 
osteoporosis. It has been suggested that hormone replacement therapy not be added to 
bisphosphonates unless the response to bisphosphonate monotherapy is insufficient. 
When patients cannot tolerate bisphosphonates, or there are concerns about safety (eg, 
in younger patients), calcitriol is an alternative. Calcitriol can protect the spine, but 
not the hip joints, from osteoporosis. (Ehab .2001) 
 
INTRODUCTION TO CYTOKINE BASED THERAPIES 
Cytokines frequently have multiple biologic functions with overlapping 
effects. Often they have proinflammatory as well as anti-inflammatory 
activity,although in most cases they can be classified predominantly as 
proinflammatory or anti-inflammatory cytokines. The therapeutic effects of cytokine 
targeted therapies also depend on the type of product, dose, dosing schedule, route of 
administration, mechanism of action, and patient population studied. Interleukin-1P 
(IL-lb) and TNF-a are the key proinflammatory cytokines implicated in the 
pathogenesis of RA. Secreted by synovial macrophages, IL- 1 p and TNF-a stimulate 
synovial cells to proliferate and produce collagenase, thereby inhibiting proteoglycan 
synthesis, degrading cartilage, and stimulating bone resorption. These cytokines 
induce the expression of adhesion molecules, resulting in further inflammatory cell 
recruitment and release of cytokines. As a prominent mediator of the inflammatory 
response, TNF-a secretion stimulates release of IL-lp and IL-6 as well as other 
cytokines and metabolites of arachidonic acid & regulated overproduction of TNF-a 
in transgenic mice results in the development of a chronic polyarthritis resembling 
RA. A variety of proteins regulate the effect or functions of cytokines in vivo and 
have been recombinantly constructed as therapeutic agents designed to inhibit IL- 1 p 
and IL- 1 a. These include soluble-receptor antagonists and antibodies to cytokines. 
Soluble receptors are truncated forms of the cell surface receptor devoid of the 
transmembrane and intracytoplasmic domains that still retain binding affinity 
comparable to the full-length membrane-bound receptors. Soluble-receptor molecules 
bind free cytokine, inhibiting its binding to cell surface receptors. To be effective, 
they must be retained within the circulation. A variety of constructs have been 
generated by fusing the immunoglobulin G subclass (IgGl) Fc region sequences to 
soluble cytokine receptors, thereby increasing affinity for the cytokine and prolonging 
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their half-life in the circulation. In comparison, anticytokine monoclonal antibodies 
have much higher (lOOO-fold) affinity and can bind cell surface-bound as well as 
free cytokine. They are smaller, possibly enabling a wider distribution, and often have 
a longer circulating half-life.  (Strand) 
 
NEW DRUGS OF CYTOKINE BASED THERAPIES 
Several promising new drugs have been approved by the FDA for the 
treatment of RA. These new medications include leflunomide, etanercept, and 
infliximab. 
 
Leflunomide 
Leflunomide is a new isoxazole immunomodulatory drug  that acts through 
inhibition of de novo pyrimidine synthesis in activated T cells by selective inhibition 
of dihydrorotate dehydrogenase. Thus the drug may be said to have antiproliferative 
activity against T cells. Preliminary data suggest that leflunomide could be used not 
only as an alternative to MTX as first-line treatment in RA but also in combination 
with MTX in patients who are unresponsive to MTX monotherapy. Leflunomide has 
the advantages of rapid onset of action (-4 weeks after the initiation of therapy) and 
significant slowing of disease progression, demonstrated by radiographic findings. 
Therefore, leflunomide may be considered a DMARD. Leflunomide is a prodrug 
given orally and metabolized in the intestine and liver to an active form that reaches 
its peak level in plasma within 8 to 12 hours. The active drug is metabolized further 
and excreted in urine and feces with an elimination half-life of 2 weeks. It is usually 
given in FU at a loading dosage of 100 mg/d for 3 days followed by a maintenance 
dosage of 20 mg/d. The adverse effects of the drug include reversible alopecia, 
diarrhea, elevated hepatic aminotransferase activity, and weight loss. The drug is 
considered teratogenic in animals and, therefore, should not be used by pregnant 
women. Interactions have been reported between leflunomide and cholestyramine.  
The latter drug binds to leflunomide in the intestine, decreasing its absorption. 
Furthermore, cholestyramine increases the rate of clearance of leflunomide from the 
body. Therefore, cholestyramine may be used in case of leflunomide toxicity. 
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Etanercept 
The biologic agent etanercept  is a recombinant version of soluble human 
tumor necrosis factor receptor (sTNFR) approved by the FDA for the treatment of 
RA. Tumor necrosis factor (TNF) is one of the major cytokines responsible for 
induction of inflammation in RA. In the synovium of the joint, TNF binds to cell 
surface receptors p55 and p75, stimulating synoviocyte proliferation and production 
of inflammatory mediators. This leads to recruitment of inflammatory cells and joint 
destruction. The sTNFRs, which are regulatory receptors to TNF inflammatory 
activity, are described as truncated versions of membrane TNF receptors. The role of 
sTNFRs is to prevent TNF access to p55 and p75 receptors, thus inhibiting the 
inflammatory activity of TNF. In RA, sTNFRs are expected to be reduced in number, 
allowing extensive binding of TNF to their own receptors (~55 and ~75) with 
consequent induction of inflammation. Etanercept is a competitive inhibitor of the 
binding of TNF to p55 and p75 receptors. If used in RA, it is usually given alone or in 
combination with MTX in patients who are not responding to MTX monotherapy or 
therapy with other DMARDs. In patients with RA who failed to improve with  
DMARD, subcutaneous administration of etanercept 16 mg/m twice weekly or as a 
fixed dose of 25 mg/wk achieved a clinical response rate of 20% as defined by the 
American College of Rheumatology (ACR). In RA patients who did not respond to 
MTX after 6 months, addition of etanercept 15 to 25 mg/wk achieved a clinical 
response of 220% as defined by the ACR. Discontinuing etanercept monotherapy in 
RA leads to recurrence of the disease symptoms within month after drug withdrawal. 
Etanercept is usually given by subcutaneous injection 25 mg twice weekly. The drug 
is generally well tolerated, but it can produce local inflammation at the site of 
injection. Patients with life-threatening infection should discontinue etanercept 
therapy. 
 
lnfliximab 
Infliximab is a chimeric human/mouse monoclonal antibody approved by the 
FDA for treatment of Crohn’s disease and RA. It binds to TNF-alpha and neutralizes 
it. Administration of the drug as a single intravenous infusion of 10 mg/kg body 
weight in patients with RA who failed treatment with DMARD resulted in 
significantly greater clinical improvement compared with placebo. The duration of 
response to the drug, which varied from 1 to 19 weeks, appeared to decrease with 
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repeated infusions. In patients with RA refractory to MTX, the combination of 
infliximab and MTX was found to be more effective than either of the 2 drugs alone. 
These 2 drugs should be administered concomitantly to guard against development of 
antibodies against infliximab, since these antibodies may limit both the duration of 
action and maximal response to the drug. Reported adverse effects of infliximab 
therapy include hypersensitivity reactions (eg, fever, chills, urticaria, dyspnea, and 
hypotension), lupus-like reactions, and increased incidence of infection. Etanercept 
and infliximab treatment should be reserved for patients who fail to respond to 
DMARD therapy. They may be given either alone or in combination with MTX. 
However, further studies should be conducted to assess the long-term safety and 
efficacy of these new agents as well as their role in combination therapy for RA. 
(Strand) 
 
EXPERIMENTAL THERAPIES 
Research on the treatment of RA continues, and the efficacy of other new 
agents is being investigated. Among the therapies currently being assessed are 
biologic agents, gene therapy, vitamin E, and stem cell transplantation. 
 
Anti-CD4 Monoclonal Antibodies 
Anti-CD4 monoclonal antibodies (anti-CD4MAb) are biologic agents directed 
against CD4 T cells. These cells are involved in the initiation of RA through 
promotion of humoral and cell-mediated immune responses. Anti-CD4MAb may 
exert an effect via several mechanisms: immunosuppression by depletion of T cells, 
inhibition of class II major histocompatibility complex-dependent T-cell responses by 
blocking the interaction of CD4 T cells with antigen presenting cells, or transmission 
of an inhibitory signal to the CD4+ cells. Because of the immunogenic reactions 
induced by murine anti-CDCMAb initially assessed as therapeutic agents in RA, 
chimeric and humanized MAb are now used in clinical trials. They are less 
immunogenic. Early studies of chimerit anti-CD4MAb therapy in patients with RA 
resulted in marked and prolonged reduction of circulating CD4 T cells without a 
parallel reduction in synovial tissue CD4 T cells. Therefore, insufficient clinical 
benefit associated with the high risk of fatal infection was reported in these trials. The 
biotechnology industry has created increasingly humanized MAb with the hope of 
minimizing immunogenicity, inhibiting functions of relevant T cells, and minimizing 
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depletion of circulating T cells. They are called nondepleting humanized anti-CD4-
MAb and are now being studied as treatment for RA. The preliminary results are 
encouraging. 
 
Interleukin-1 Receptor Antagonist 
IL-l receptor antagonist (IL-lra), a biologic agent, is an anti-inflammatory 
cytokine produced primarily by activated monocytes and tissue macrophages. In RA 
the concentrations of IL-l are increased in the synovial fluid of affected joints. 
However, this increase may be insufficient to inhibit the IL-l-induced inflammatory 
response occurring in RA. Administration of IL-l at a dosage of 150 mg/d in patients 
with RA achieved a modest inhibition in both joint swelling and radiographic 
evidence of progression of bone lesions. No side effects were reported, except 
transient injection-site reactions. IL-l is the first biologic agent to demonstrate a 
significant reduction in the rate of joint damage in patients with RA.  Therefore, it is 
considered an important novel therapeutic option for future management of RA. 
 
Interleukin-10 
IL-10 is a natural anti-inflammatory cytokine produced mainly by monocytes. 
Its physiologic functions include inhibition of proinflammatory cytokines (IL-1 and 
TNF) and antigen-presenting cell function.IL-10 expression in the synovial fluid and 
serum increases in patients with RA, where it may serve as a buffer or natural 
inhibitor of the activities of several proinflammatory cytokines. However, an 
insufficient amount of IL-10 is produced to effectively suppress the inflammatory 
response. A multicenter, randomized, double-blind, placebo controlled study 
investigated the use of recombinant human IL-10 in active IL-10 5 mg/kg per day was 
administered subcutaneously for 28 days. Trends toward clinical improvement of 
220% as defined by the ACRs were observed in patients treated with IL-10 compared 
with placebo. Further more, DMARD usage during the 2 months following therapy 
was reduced in IL-10 treated patients versus placebo patients. It is said that IL-10 
administration in RA may produce a reparative effect within the diseased joints 
through stimulation of synthesis of proteoglycan, which is necessary for regeneration 
of damaged joints and cartilage. 
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Gene Therapy 
Gene therapy, the transfer of genes to patients for therapeutic purposes, is 
being used in the treatment of RA for a number of reasons. First, current steroidal and 
nonsteroidal treatments have limited efficacy and a high incidence of side effects. 
Second, biologic agents must be administered subcutaneously or intravenously at least 
once weekly, and disease symptoms return when treatment is stopped. Furthermore, 
susceptibility to infection may increase when using immunomodulatory molecules 
such as TNF and IL-l systemically in RA. Finally, local injection of biologic agents 
into joint spaces is followed by rapid clearance of these recombinant proteins from the 
synovial fluid. In this condition, daily injections may be indicated. When a gene that 
encodes therapeutic proteins is administered into the affected joint, it enables the joint 
itself to produce high local levels of these therapeutic mediators that can subsequently 
inhibit inflammation, synovial proliferation, and cartilage destruction. In animal 
models with collagen-induced arthritis, injection of antiarthritic genes into single 
arthritic joints could produce an antiarthritic response in uninjected joints of the same 
animal.  This observation suggested that transduced cells traffic from injected to 
uninjected joints. Accordingly, there is no need to inject diseased joints individually 
when applying gene therapy in polyarticular diseases such as RA. The first clinical 
trial of gene therapy in patients with RA was initiated in 1996 at the University of 
Pittsburgh. In this trial, a retroviral vector carried the gene for human IL-l. The vector 
was injected into 2 of the 4 metacarpal joints of the right hand with the other 2 joints 
receiving unmodified cells. One week later, the joints were removed and the 
recovered tissues were analyzed for gene expression and changes in pathophysiology. 
In the 7 patients who completed the trial, gene expression was detected in all of the 
appropriate joints with no apparent toxicity. The rate-limiting step to successful 
application of gene therapy in RA is the ability to deliver genes efficiently and 
repeatedly to joints without inducing pathology. It is not yet likely that gene therapy 
will be routine treatment for RA. (Ehab .2001) 
 
Antioxidants 
In the last few years, antioxidants, particularly vitamin E, have received 
considerable attention in the treatment of human diseases. In rheumatic diseases, 
active phagocytes and leukocytes migrate into synovial and periarticular tissues 
causing liberation of active oxygen species that exacerbate and perpetuate the 
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rheumatoid condition. Thus in rheumatology, treatment with antioxidants has received 
much interest. A double blind randomized study investigated the possible analgesic 
and anti-inflammatory properties of orally administered tocopherol (vitamin E) at a 
dosage of 600 mg twice daily compared with placebo for 12 weeks in patients with 
RA.  The study showed that vitamin E was effective in reducing pain but had no anti-
inflammatory effect. In another study, vitamin E (1200 mg/d) was compared to 
diclofenac sodium for 3 weeks in patients with chronic RA. The study demonstrated 
similar therapeutic efficacy of both drugs with respect to pain relief and duration of 
morning stiffness. 
 
The risk profile of NSAIDs in long-term treatment of chronic RA makes 
administration of high-dose vitamin E a possible alternative in the treatment of 
inflammatory rheumatoid diseases. (Strand) 
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REVIEW OF LITERATURE 
1) Rajesh Kumar, et al., (2009) has conducted the hepatoprotective activity of 
aerial parts of Plumbago zeylanica against Carbon tetra chloride – induced 
hepatotoxicity in rats. Silymarin (100mg/kg, p.o.) was given as reference drug. 
The extract of aerial parts of Plumbago zeylanica have been reported to have 
significant hepatoprotection against CCl4-induced hepatotoxicity in wistar rats 
by reducing serum total bilirubin, SGPT ,SGOT and ALP levels. 
Histopathological studies also confirmed the hepatoprotective nature of the 
extract.
[10] 
 
2) Maryamzahin, et al., (2009) has studied the in vitro antioxidant activity and 
total phenolic content of four Indian medicinal plants. Methanolic extracts of 
Plumbago zeylanica (Root), Acorus calamus (Rhizome), Hemidesmus indicus 
(Stem) and Holarrhena antidysenterica (Bark), were evaluated for their 
antioxidant activity by ferric thiocyanate (FTC) assay and compared with 
thiobarbituric acid (TBA) method. Further, the radical-scavenging activity of 
the extracts was measured as decolorizing activity followed by the trapping of 
the unpaired electron of DPPH. The findings indicated promising antioxidant 
activity of crude extracts of the above plants.
[11] 
 
3) Vineet Mittal, et al., (2010) had conducted a comparative study of analgesic 
activity of Plumbago zeylanica callus and root extracts in experimental mice. 
The activities were evaluated for peripheral and central analgesic activity by 
glacial acetic acid induced writhing and tail immersion model respectively. In 
conclusion, a massive light creamish brown and granular callus formed with 
MS medium supplemented with naphthalene acetic acid (1.5 ppm) and kinetin 
(0.25 ppm) and it possess a significant peripheral analgesic activity.
[12] 
 
4) Vishal Gupta, et al., (2011) has evaluate the wound healing activity of herbal 
drug combination of Rubia cordifolia, Centella asiatica, Terminalia belerica, 
Plumbago zeylanica and Withania somnifera on excision wound of albino rats. 
The activity of the plant was evaluated by formulating the drug in ointment 
dosage form and then compared with a marketed formulation (Soframycin 
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cream) as reference drug. The parameters studied include the percentage 
closure of excision wound, period of epithelization.
[13] 
 
5) Kanchana, N, et al., (2009) has evaluated the hepatoprotective effect of 
plumbago zeylanica on paracetmol induced liver toxicity in rats. In serum total 
bilirubin, total protein, aspartate transaminase, alanine transaminase,   alkaline 
phosphatase, lactate dehydrogenase, γ‐Glutamyl transferase, Total Cholesterol 
and serum triglycerides were determined to assess the effect of the extract on 
the paracetamol induced hepatic damage. The study was also supported by 
histopathology of liver sections.
[14] 
 
6) Sasi kumar, et al., (2010) has conducted the HPTLC   analysis of various 
market samples of a traditional drug source –Kodiveli (Plumbago zeylanica).  
The present study deals with Plumbagin, 5‐hydroxy‐2methyl‐1, 
4‐napthoquinone, an active chemical constituent of the root of this plant drug. 
This bioactive molecule is a proven anticarcinogenic, antiatherosclerotic and 
antimicrobial agent.
[15] 
 
7) Jyoti Ranjan Rout, et al., (2010) has evaluated the In Vivo Protein Profiling 
and Catalase Activity of Plumbago zeylanica. Traditionally it is used as 
carminative, anthelmintic, to cure inflammation, piles etc. In the first part of 
our study, total protein content (11.1±2.6mg/ gm of fresh leaf) was estimated 
from leaf sample of P. zeylanica in the second part, the catalase activity was 
studied from the leaf sample. In this study it was found that P. zeylanica 
contained several protein bands of molecular weight 50.08, 41.25, 38.41, 
36.21, 28.74 and 25.52kDa and the total catalase activity was 168.40±7.28 
nKat/min/mg of protein.
[16] 
 
8) Barasa M Maniafu, et al., (2009) has studied the larvicidal activity of extracts 
from three Plumbago species against Anopheles gambiae. The crude extracts 
exhibiting the highest larvicidal activity against Anopheles gambiae were 
hexane (LC50 = 6.4 μg/mL) and chloroform (LC50 = 6.7 μg/mL) extracts 
from Plumbago zeylanica Linn.
[17] 
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9) Lie-Chwen Lin, et al., (2003) has studied the Cytotoxic naphthoquinones and 
plumbagic acid glucosides from Plumbago zeylanica. Two plumbagic acid 
glucosides, 30-O-b-glucopyranosyl plumbagic acid and 30-O-b-
glucopyranosyl plumbagic acid methylester along with five naphthoquinones 
and five coumarins were isolated from the roots of Plumbago zeylanica. 
Cytotoxicity of these compounds to various tumor cells lines was evaluated, 
and plumbagin significantly suppressed growth of Raji, Calu-1, HeLa, and 
Wish tumor cell lines.
[18] 
 
10) Navneet Kishore, et al., (2010) has isolate Difuranonaphthoquinones from 
Plumbago zeylanica roots. The naphthoquinones, lapachol (1), plumbagin (2), 
2-isopropenyl-9-methoxy-1,8-di-oxa-dicyclopenta[b,g]naphthalene-4,10-dione 
(3), 9-hydroxy-2-isopropenyl-1,8-dioxa-dicyclopenta[b,g]naphthalene- 4,10-
dione (4), 2-(1-hydroxy-1-methyl-ethyl)-9-methoxy-1,8-dioxa-
dicyclopenta[b,g]naphthalene- 4,10-dione (5) and 5,7-dihydroxy-8-methoxy-
2-methyl-1,4-naphthoquinone (6) were isolated isolated from roots of 
Plumbago zeylanica. The new constituents in addition to known compounds 
were characterized by spectral analysis (UV, IR, 1D & 2D NMR and MS).
[19] 
 
11) Vijayakumar, R, et al., (2006) has evaluated the Plumbago zeylanica action on 
blood coagulation profile with and without blood volume reduction .The 
structure of its active principle is similar to that of vitamin K. The individual 
groups were screened for its effect on bleeding time (BT), clotting time (CT), 
prothrombin time (PT), platelet count and platelet adhesion in albino rats after 
1-day, 15-day and 31-day treatment. There was no change in the platelet count 
in the treated groups when compared to the control levels. But the platelet 
adhesion was significantly decreased after PZ and also napthaquinone-treated 
animals in both with and without blood volume reduction after 15th as well as 
31st day.
[20] 
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12) Kefale teshome, et al., (2008) has done the toxicity studies on dermal 
application of plant extract of Plumbago zeylanica. To this effect, the 
dermatotoxicity of 80% methanol extract of the root part of Plumbago 
zeylanica was investigated in animals following standard procedures for 
irritation, sensitization, acute toxicity and repeated toxicity tests. Extraction of 
plant material with 80% methanol resulted in 9.45% of crude extract of 
Plumbago zeylanica. Taken together, the dermatotoxicity test results from this 
study suggest that Plumbago zeylanica toxic effects might be limited to effects 
like moderate irritation.
[21]
 
 
13) Ravikumar , et al.,   (2011)  has  studied   petroleum  ether ,ethanol  and  
aqueous  extract  of  leaves  and  stems  of  plumbago  zeylanica  were  used  
against  bacteria  and  fungi  by  paper  disc  method .  Gentamycin and 
Amphotericin – B were used as standard drug.  The  result  suggest that 
ethanol  and  petroleum  ether  extract  showed  moderate  anti-  bacterial  
activity  and  aqueous  extract  did  not  active  against  negative   bacterial  
species.  In  antifungal  ,  it  was  found  that  among  the  extracts  and  
compare  with  standard ,  ethanol  extract  showed  a  significant  anti-fungal  
activity.
[22] 
 
14) Aparanji poosarla ,et al.,(2010)   has  investigated   the  potential  
immunosuppressive  property by  testing  the  aqueous extracts  of the  
plumbago  zeylanica parts  by  inducing  ovalbumin  specific  IgG  antibody  
responses  in  murine  system.  The  Aqueous  root  extract  of  plumbago  
zeylanica  exhibited  the  significant  suppression  OVA-  specific  IgG 
antibody  response  determined  by  enzyme-linked  immunosorbent  assay  
(ELISA).
[23]  
 
15) Vineet  Mittal ,  et al.,(2010)  has  investigated  the  effect  of  plumbago  
zeylanica  roots  on  learning  and  memory  of  mice.  The  study  was  carried  
out  in  extroceptive  and  introceptive  behaviour  model  .  The  chloroform  
extract  of  plumbago  zeylanica (100,200 and 400 mg/kg) Was  administered   
for 10  successive  days  in  separate  group  of  animals.  This   shows   
promising memory enhancing effect.
[24]
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16) Sachin  Hiradeve,  et al .,(2009)  has  evaluvated  the  ethanolic  extract  of 
plumbago  zeylanica  Linn.  Possessed  significant  anticancer  activity  against  
Ehrlich  ascites  carcinoma  in  animal  model.  This  is  due  to  the  leaf  
extract  contains  higher  amount  of  terpenoid  and  flavanoid  content 
.[25] 
 
17) Vishnukanta,  et al.,(2010)  has  investigated  leaf  extract  of plumbago  
zeylanica  shows  anticonvulsant  activity  in  mice  and  rat  using  PTZ  
induced  convulsion   and  maximum  electro  shock  induced  convulsion.
[26] 
 
18) Devender  Rao  Kodati , et al., (2011)  has   evaluated  methanolic  root  
extract  of  plumbago  zeylanica are  having  significant  wound  healing  
activity  in  rats.
[27]
   
 
19) R Jeychandran ,  et al., (2009) has  studied  plumbagin   and  chloroform  
extract  of  plumbago  zeylanica  L.  Root   showed antibacterial activity 
against Escherichia coli, salmonella typhi and staphylococus aureus. The  
methanolic  extract  exhibited moderate   activity  and  aqueous  extract  weak  
activity  against the  bacterial  strains  as  assessed  by  disc  diffusion 
assays.
[28] 
 
20) Kantha  Arunachalam  ,  et al.,(2010)   has  conducted   a  comparitative  study   
of  Anti-inflammatory andcytotoxic effects of plumbago zeylanica. The root of  
plumbago  zeylanica  extracted  with  methanol  was  used  for  determining  
anti- inflammatory   effects .In  carrageen in  induced  raw  paw  oedema   
confirming   that  plumbago  zeylanica  roots  are  effective  against  acute  
inflammation .  For  evaluation  of  cytotoxicity,  the  crude  dichloromethane 
extract  was  subjected  to  silica gel  column  chromatography . Their  
structure  were  elucidated  with  the  help  of  spectroscopic  techniques.
[29]
 
 
21) Chen- Anchen, et al. , (2008)  has  evaluvated  the  plumbagin  isolated  from  
plumbago  zeylanica  shows  anticancer  or  anti  tumour  effect  against  
pancreatic  cancer.
[30]
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22) Ajayi ,  et al . ,  (2011)  has  studided   the  phytochemical  component  present  
in  the  ethanolic  root  extract  of  the  plant  by  phytochemical  screening  
methods  and  GC-MS  Analysis.  The   phytochemical   screening   showed 
the presence of alkaloids, tannins, Steroids, flavanoids,  saponins ,   
anthraquinones,  cardiac- glycosides,  phlobatinnins And carbohydrates. The  
GC- MS analysis  also  identified  the  presence  of  phytochemical 
components  like  phenolics, cyclopentadecane, fatty  acid,  Feroprone etc.
[31]
 
 
23) Marym zahin  ,  et al., (2009)  has  conducted  the  in vitro  antioxidant  
activity   and  total  phenolic  content  of  four  medicinal  plants   the  present  
study  deals  with  methanolic  extract  of  plumbago  zeylanica  (root) ,  
Acoras  calamus (Rhizome) ,  Hemidesmus  indicus (stem)  and Holarrhena 
antidysentrica (Bark)  evaluvated  for  their  antioxidant  activity  by  ferric 
thiocynate (FTC)  assay  and  thiobarbituric  acid  (TBA)  method.
[32] 
 
24) Bharathi  raja  subramaniya  , et al., (2000)  has  investigated   the  anti 
proliferative  and  apoptotic  activity  of  plumbagin  by  using  two  human  
colonic  cancer  cell  lines ,HT29 and  HCT 15.
[33] 
 
25) Alpanaram, et al. ,  (1996)  has  evaluvated   the  effect  of  ethanolic   extract   
of  plumbago  zeylanic  and  combined  with   vitamin  E  was   studied  in  
experimentally  induced  hyperlipidemic  rabbit.   There  was  significant  
reduction  in   serum  total  cholesterol , LDL ,  cholesterol and  triglycerides  
level.
[34]. 
 
26) Meena ,  et al .,   (2009)   has  conducted   root  of  plumbago  zeylanica  was   
subjected   to  macro-microscopic,  physic- chemical,  preliminary 
photochemical,  TLC  to  fix  the   quality  of   standard  drug.   This   
experiment   yielded   as set of   diagnostic characters like cork cell, stone cell, 
parenchyma.  This  study  would  be  useful  for   standardization  of  this  raw  
drug  derived  from  root of  plumbago zeylanica.
[35] 
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27) Chellampillai  bothiraja,  et al ., (2011)   has   studied  the roots of P. zeylanica 
were cold macerated with a mixture of chloroform/dichloromethane (1:1) and 
the extract was s washed with water, saturated sodium bicarbonate and water . 
The concentrated washed extract was dissolved in n-hexane and recrystallized 
to get plumbagin. The isolated and standard plumb gin was subjected to DSC, 
HPTLC, UV, FTIR, 1H and 13C NMR and mass spectroscopy studies for   
assessment of chemical structure and   purity.
[36] 
 
28) Kamal, et al., (1982)  has  evaluated   isolation of plumbagin , droserone, 
isoshinanolone and a new naphthalenone, 1,2(3)-tetrahydro-3,3’-biplumbagm 
is reported from the phenolic fraction of the high petrol extract of the roots of 
Plumbago zeylanzca. The structure of the new naphthalenone was elucidated 
by means of spectroscopic data and chemical conversions. The main   
constituent of the neutral fraction was shown to be sitosterol
.[37]
     
 
29) Akella , et  al  .  , (1975)   has   conducted   the isolation of six pigment  from 
the  and  plumbago  zeylanica   identification of three of these as plumbagin 
(2-methyl-5hydroxy-1,4-naphthaquinone, PZ 4), 3chloroplumbagin(PZ 3) and 
3,3’-biplumbagin (PZ 6)  .  From the Present study a new biplumbagin . It has 
been named chitranone, is a juglone derivative from its colour   reactions, UV 
and IR spectra.
[38]
   
 
30) Kefele Teshome ,  et al. , (2008)  has studied  Plumbago zeylanica, a 
medicinal plant commonly for skin diseases was subjected to asymtomatic 
dermatotoxicity study . To this effect, the dermatotoxicity of 80% methanol 
extract of the root part of Plumbago zeylanica was investigated in animals 
following standard procedures for irritation, sensitization, acute toxicity and 
repeated toxicity tests. Extraction of plant material with 80% methanol 
resulted in 9.45% of crude extract of Plumbago zeylanica . The skin irritation 
test on rabbits Plumbago zeylanica extract to be a moderate irritant, with a 
primary irritation index of 2.00. Sensitization test on mice by the Mouse Ear 
Swelling Test method revealed the extract to be non-sensitizer in a dose range 
of 4–10 mg/ml and the percent responder was zero.  Acute dermal toxicity test 
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on rats did not produce any overt signs of toxicity, except that there was a 
weight gain difference between the test and control groups   of female rats.The 
dermatotoxicity test results from this study suggest that Plumbago zeylanica 
toxic effects might be limited to effects like moderate   irritation
[39] 
 
 
31) Gupta   sandeep, et al. ,  (2011)  has  evaluated  the effect of plumbagin-free 
alcohol extract (PFAE) of Plumbago zeylanica  root, on female reproductive 
system and fertility of Adult female wistar rats . All findings suggest that the 
anti fertility activity of extract could possibly   be  through  the  change  in  the  
implantation  site  ,  altered  hormonal  level ,  prolonged   estrous  cycle  and  
anti-  estrogenic activity.   Hence the extract possesses reversible   anti fertility   
activity without   adverse toxicity in females.
[40] 
 
32) Kamal ,  et al  . , (2004)   has reported   the synthesis   of plumbazeylanone, a 
quinine From  Plumbago  zeylanica  is  probably 5b,11a, 12, 12a tetrahydro-
1,7 dihydroxy -5b-(-8-hydroxy-3-methyl-1,4-naphtoquinone-2-yl)-  5a,12a-
dimethyl-5aH-dibenzo[b,h] fluorine-5,13:6,11-diquinone , a novel trimer  of   
plumbagin  with  additional methyl  group 
[41]
 
 
33) Sathya Shanmugaraja , et al ., (2010) has studied , the anti-invasive activities 
of P. zeylanica  methanolic extract (PME) and pure compound 3_-hydroxylup-
20(29)-ene-27,28-dioic acid (PZP) isolated from it are investigated in vitro. 
PME and PZP were noted to have the ability to induce apoptosis as assessed 
by flow cytometry. Further, the molecular mechanism of apoptosis induced by 
PME and PZP was found by the loss of mitochondrial membrane potential 
with the down regulation of Bcl-2, increased expression of Bad, release of 
cytochrome c, activation of caspase-3 and cleavage of PARP leading to DNA 
fragmentation Importantly, both PME and PZP were observed to suppress 
MDA-MB-231 cells adhesion to the fibronectin-coated substrate and also 
inhibited the wound healing migration and invasion of MDA-MB-231 cells 
through the reconstituted extracellular matrix. Gelatin zymography revealed 
that PME and PZP decreased the secretion of matrix metalloproteinases-2 
(MMP-2) and metalloproteinases-9 (MMP-9).Interestingly both PME and PZP 
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exerted an inhibitory effect on the protein levels of p-PI3K, p-Akt, p-JNK,p-
ERK1/2, MMP-2, MMP-9, VEGF and HIF-1_ that are consistent with the 
observed anti-metastatic effect
[42] 
 
34) Iwao Okamoto, et al.,   reported the direct biomimetic   synthesis of 3, 3%-
biplumbagin, isolated from Plumbago zeylanica 2,2%-binaphthols was 
developed, utilizing aryl–aryl coupling reaction via electron donor–acceptor 
complexes of 1-naphthols with SnCl4. Heating of the complex in a sealed tube 
afforded the corresponding o-o coupling product in excellent yield. This 
method was utilized for a biomimetic synthesis of the binaphthoquinone,3 
,3%-biplumbagin, isolated from Plumbago zeylanica . 
[43]
 
 
35) Gebre-Mariam  ,  et al., (2005)  has  evaluated  antiviral  activity  of  some  
herbal  Drug   combination   of  Acokanthera schimperi (Apocynaceae ), 
Euclea schimperi (Ebenaceae), Inula confertiflora (Asteraceae), Melilotus 
elegans (Leguminosae), and Plumbago zeylanica (Plumbaginaceae) the 
antiviral activities of the 80% methanolic extracts of these plants have been 
examined against coxsackie virus B3 (CVB3), influenza A virus and herpes 
simplex virus type1 Kupka (HSV-1) using cytopathic effect (CPE) inhibitory 
assays in HeLa, MDCK, and GMK cells, respectively. 
[44] 
 
 
36) Demma, et al., (2009)   has   conducted   potential   genotoxicity   of   herbal  
drug  Combinations hydroalcoholic extracts of Glinus lotoide, Plumbago 
zeylanica, Rumex steudelii and Thymus schimperiwere were evaluated for their 
DNA damaging effects using the comet assay in Mouse lymphoma L5178Y 
cells In the absence of S9, all extracts were found to induce significant DNA 
damage without affect in the cell viability. T. schimperi and R. steudeliiwere 
the most potent DNA-damaging extracts, and G. lotoidesand P. zeylanica the 
least potent. The addition of S9 had different effects on the DNA damage 
induced by the extracts: It lowered the DNA damaging effect of P. zeylanica, 
did not affect the DNA damaging effectof T. schimperi, and increased the 
DNA damaging effects of R. steudelii and G. lotoides The findings of the 
present study suggest that all extracts evaluated have a genotoxic   potential in 
vitro
.
 
  [45]
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37) Seiichi Sakamoto, et al., (2008)  has investigated  Development of an enzyme-
linked immunosorbent assay(ELISA) using highly-specific monoclonal 
antibodies  against plumbagin . plumbagin (PL; 5-hydroxy-2-methyl-1,4-
naphthoquinone) is a natural compound mainly isolated from Plumbago 
zeylanica. Plumbagin   has been shown to have various pharmacological 
activities.  Assay (ELISA) system for determination of PL. 3-(5-Hydroxy-2-
methyl-1,4-naphthoquinone-3-yl) propanoic acid was synthesized and purified 
to prepare PL–bovine serum albumin conjugate (PL–BSA), which was used as 
an immunogen. PL–BSA conjugate was administered into BALB/c male assay 
(ELISA) system for mice for production of monoclonal antibodies against PL. 
The monoclonal antibody against PL which is secreted from established 
hybridoma cell line 3A3 (MAb 3A3) has been proven to have highly-specific 
to PL resulting from cross- reactivity test. The range for calibration of PL by 
ELISA was 0.2–25_gmL−1. Based on validation analysis, this analytical 
method by ELISA is a precise, accurate, and sensitive method for the 
determination of PL in plant  
 
.
  [46]  
 
38) Yen-Ju Hsieh, et al., (2006)   finds to develop an automated blood sampling 
(ABS) method coupled to a liquid chromatography–tandem mass spectroscopy 
(LC–MS/MS) method to evaluate the oral bioavailability of plumbagin in a 
conscious freely moving rat. Plumbagin, an herbal ingredient, was isolated 
from Plumbago zeylanica. The separation was performed using a reversed 
phase C18 (150mm×4.6mm I.D.; 5_m) column and was eluted with the mobile 
phase of water–acetonitrile (40:60, v/v) at a flow-rate of 0.8 ml/min. Multiple 
reaction monitoring (MRM) was used to monitor the transition of the 
deprotonated molecule m/z 187 [M H]  to the product ion m/z 159 [M H CO]− 
for the plumbagin analysis. The calibration curve was linear over the 
concentration range of 10–2000 ng/ml with a coefficient estimation of 0.995. 
The intra- and inter-day variations (% relative standard deviation; RSD and % 
bias) of the assay for rat plasma samples were less than 17%. The limit of 
detection and the limit of quantification were 5 and 10 ng/ml, respectively. 
Recovery of plumbagin from the rat plasma was about 80%. This LCMS/MS 
method has been validated to study the pharmacokinetics plumbagin was 
about 38.7±5%. 
[47] 
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39) Akella ,  et al.,  (1978)  has  studied sThe  isolation  of  Zeylanone And  
Isozeylanone   two  novel  quinines , from  plumbago  zeylanica  .   
[48]
777774
 
 
40) Lie-Chwen Linn, et al., (2002)   has   isolated two plumbagic acid glucosides, 
30-O-b-glucopyranosyl plumbagic acid and 30-O-b-glucopyranosyl plumbagic 
acid methylester along with five naphthoquinones (plumbagin, chitranone, 
maritinone, elliptinone and isoshinanolone), and five coumarins (seselin,5-
methoxyseselin, suberosin, xanthyletin and xanthoxyletin) were isolated from 
the roots of Plumbago zeylanica  and  Cytotoxicity of these compounds to 
various tumor cells lines was evaluated. 
[49]
 
 
41) Yen-Ju Hsieh, et al., (2005)   has   studied liquid chromatography coupled 
with tandem mass spectrometric (LC–MS/MS) method for the determination 
of plumbagin form plumbago zeylanica.  
  [50] 
 
42) Yuan-Chuen Wan.  , et al., (2005) Thas investigated plumbagin’s anti-H. 
pylori activityand developed a reversed-phase high-performance liquid 
chromatography (HPLC) method for quantification of plumbagin from P. 
zeylanicaaL. And observed that plumbagin has strong anti-H.Pylori activity, 
with 0.02–0.16 mg/ml as minimum inhibitory concentrations and 0.16–1.28 
mg/ml as minimum bactericidal concentrations. 
[51]
 
 
43) Kamal .Gunaherath, et al., (1982)     has    investigated   a method  to  develop   
plumbagm, droserone, isoshinanolone and a new naphthalenone, 1,2(3)-
tetrahydro-3,3’-biplumbagm is reported from the phenolic fraction of the light 
petrol extract of the roots of Plumbago zeylanzca. The structure of the new 
naphthalenone was elucidated by means of spectroscopic data and chemical 
interter conversions. The main constituent of the neutral fraction was shown to 
be sitosterol .  
[52]
 
 
44) Navneet Kishore ,et al., (2009)  has  examined   the   isolation  of  
Difuranonaphthoquinones  such as naphthoquinones, lapachol (1), plumbagin 
(2), 2-isopropenyl-9-methoxy-1,8-di-oxa-dicyclopenta[b,g]naphthalene-4,10-
dione(3),9-hydroxy-2-isopropenyl-1,8-dioxadicyclopenta[b,g]naphthalene-
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4,10-dione (4), 2-(1-hydroxy-1-methyl-ethyl)-9-methoxy-1,8-dioxa-
dicyclopenta[b,g]naphthalene-4,10-dione (5) and 5,7-dihydroxy-8-methoxy-2-
methyl-1,4-naphthoquinone (6)from roots of Plumbago zeylanica .
[53] 
 
45) Yuan-Chuen et al., (2004) has   evaluated     Anti-Helicobacter pylori activity 
of Plumbago zeylanica.  
[54]
 
 
46) Tsai, et al., (2008) has studied Seselin from Plumbago zeylanica inhibits 
phytohemagglutinin (PHA)-stimulated cell proliferation in human peripheral 
blood mononuclear cells. 
[55] 
 
47) Praveen Verm , et al .,  (2001) has   evaluated   rapid micro propagation and 
establishment of higher plumbagin yielding hairy root cultures by  using  in   
vitro -  studies  in  plumbago zeylanica. Hairy roots initiated at 0.9 ± 0.05 
relative transformation frequency with the A4 strain of Agrobacterium 
rhizogenes exhibited optimum growth in half strength MS medium containing 
4% sucrose. Growth kinetic studies demonstrated a maximum 21 fold increase 
in biomass yield after 6 weeks of culture. The fresh hairy roots produced 2.5 
times higher amounts of plumbagin than the fresh, untransformed control roots 
or the dry hairy roots of the same age. The present research finding srevealed 
for the first time the potentialities of the hairy root cultures of Plumbago 
zeylanica for the production of the important secondary metabolite plumbagin. 
[56] 
 
48) Yen-Ju Hsieh ,  et al. ,  (2005)  has  evaluated  liquid chromatography coupled 
with tandem mass spectrometric (LC–MS/MS) method for  the  Determination 
and  identification  of  plumbagin form  root  of  plumbago zeylanica . 
[57] 
 
49) Navneet Kishore ,  et  al .,  (2009)  has  studied  the  isolation  
naphthoquinones, lapach(1),plumbagin(2)2-isopropenyl-9-methoxy-1,8-di-
oxdicyclopenta[b,g]naphthalene-4,10-dione (3), 9-hydroxy-2-isopropenyl-1,8-
dioxa-dicyclopenta[b,g]naphthalene-4,10-dion(4),2-(1-hydroxy-1-methyl-
ethyl)-9-methoxy-1,8-dioxdicyclopenta[b,g]naphthalene-4,10-dione (5) and 
5,7-dihydroxy-8-methoxy-2-methyl-1,4-naphthoquinone (6) from roots of 
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Plumbago zeylanica .The new constituents (3–5) in addition to known 
compounds (1, 2 and6) were characterized by spectral analysis (UV, IR, 1D & 
2D NMR and MS).   
[58]
 
 
50) Shanumugasundaram P, et al. , (2006) has  evaluated  hepato protective  and  
antioxidant  effects  of  hydrophila auriculata  root  against  ccl4  induced  
liver  toxicity  in  rats  and  ferric  thiocyanate  (FTC)  and  thiobarbituric acid  
(TBA) method  respectively .  The  activity  was  accessed   by  monitoring  
the  various  liver  function  tests  ,  viz  alanine  transaminase ,  aspartate 
transaminase (AST)  ,  alkaline phosphatase   (ALP)  ,  Total  protein  and  
total  bilirubin.  Furthermore   hepatic tissues were   subjected to 
histopathological studies.  They  concluded that  there was  a  significant  
hepatoprotective activity and  antioxidant  activity  for  aqueous  extract  of  
the  roots  of hygrophilia  auriculata .     
[59] 
 
51) Rawat ,  et al .,  (1997)   studided   hepatoprotective  activity  of  Boerhaavia 
diffusa  L.roots a popular  indian  ethanomedicine  .  In  this  study  the  effects  
of  seasons, thickness  of  roots  and  form  of  dose  were  studied for  their  
hepatoprotective  action  to  prove  the  claims  made  by  the  different 
diameters  tribes  of  india. The  hepatoprotective activity of  roots  of  
different diameters collected  in  three  seasons ,  rainy, summer, and  winter ,  
was  examined in  thioacetamide intoxicated  rats .  The  result  showed  that  
an  aqueous  extract (2ml/kg) of  roots  of  diameter 1-3 cm  ,  collected in  this  
month  may  (summer) exhibited  marked  protection  of  a  majority  of  
serum  parameters , ie. S GOT, SGPT.  
[60]  
 
52) Anubha  singh ,  et al  . , (1995)  has  evaluated the  hepatoprotective activity  
of  Apium  gaveolens  and   Hygrophila auriculata against  paracetamol  and  
thioacetamide  intoxication in  rats .  In  this  study  the  rat  liver was  
damaged by  a  single  dose  of  paracetamol  (3kg/kg:p.o) or   thioacetamide  
(100mg/kg; s.c ). They were monitoring   several liver function tests, Viz.  
serum  transaminase  (SGOT and  SGPT)  ,  alkaline  phosphatase,  sorbitol  
dehydrogenase ,  glutamate  dehydrogenase,  and  bilirubin  in  serum .  They  
concluded  that  there  was  a  significant  hepatoprotective  activity  of  the  
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methanolic  extract  of  the  seeds  of  Apium Graveolens and  Hygrophila  
auriculata.  
[61]   
 
53) Muthu Gounder Palanivel,   et al., (2008) has studied Ethanol extract of 
Pisonia aculeata (EPA) was evaluated for hepatoprotective and antioxidant 
activities in rats. The plant extract (250 and 500 mg/kg, p.o.) showed a 
remarkable hepatoprotective and antioxidant activity against carbon 
tetrachloride (CCl4)-induced hepatotoxicity as judged from the serum marker 
enzymes and antioxidant levels in liver tissues. CCl4-induced a significant rise 
in aspartate amino transferase (AST), alanine amino transferase (ALT), 
alkaline phosphatase (ALP), total bilirubin, gamma glutamate transpeptidase 
(GGTP), lipid peroxidase (LPO) with a reduction of total protein, superoxide 
dismutase (SOD), catalase, glutathione peroxidase (GPx) and glutathione S-
transferase (GST). Treatment of rats with different doses of plant extract (250 
and 500 mg/kg) significantly (P<0.001) altered serum marker enzymes and 
antioxidant levels to near normal against CCl4-treated rats. The activity of the 
extract at dose of 500 mg/kg was comparable to the standard drug, silymarin 
(50 mg/kg, p.o.). Histopathological changes of liver sample   were compared 
with respective control. Results indicate the hepatoprotective and antioxidant 
properties of P. aculeata against CCl4-induced hepatotoxicity in   rats   . 
[62] 
 
54) Deepak. k. Das, et al., (2007) has studied   the hepatoprotective effect of 
chloroform and methanol extract (CEIF and MEIF) of whole plant of I. 
frutescens (Linn.) by paracetamol-induced liver damage in rats: The 
chloroform and methanolic extracts of I. frutescens (CEIF and MEIF) were 
studied for their hepatoprotective and antioxidant effects on paracetamol 
(750mg/kg) induced acute liver damage on Wistar albino rats. The degree of 
protection was measured by using biochemical parameters such as serum 
glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate 
transaminase (SGPT), alkaline phosphatase (ALP), bilirubin and total protein. 
Further, the effects of both extracts on lipid peroxidation (LPO), glutathione 
(GSH), superoxide dismutase (SOD) and catalase (CAT) were estimated 
.CEIF and MEIF at a dose level of 250mg/kg and 500mg/kg produce 
significant (P<0.05) hepatoprotection by decreasing the leves of serum 
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enzymes, bilirubin, and lipid peroxidation , while they significantly increased 
the levels of Glutathione (GSH), superoxide dismutase (SOD) and catalase 
(CAT) in a dose dependent manner. The effects of CEIF and MEIF were 
comparable to that of standard drug, Silymarin.  From this study, it can be 
concluded that the chloroform and methanol extract of I.frutescens is not only 
an effective hepatoprotective agent, but also possesses significant (p<0.05) 
antioxidant activity. 
[63] 
 
55) Prabakaran, et al., (2011) has evaluvated a comparative antimicrobial effect 
and phytochemical screening of Plumbago zeylanica, Ocimum 
gratissimum,Bryophyllum fedtschenkoi.  were subjected to antimicrobial and 
phytochemical screening. The extraction was taken from these plants using the 
solvents ethanol, benzene and aqueous. The ethanolic extracts of plant leaves 
showed significant activity against bacterial and fungal pathogen and results 
were unpored with standard antibiotics such as Ampecillin, Penicillin 
Streptomycin Griscofulevnin, ampotericin and fluconazole. The phytochemical 
component were identified by using thin layer chromatographic and the results 
further technique and the  supported that some Indian medicinal plants 
possess. Potential antimicrobial compounds which will be used cure most of 
the diseases. 
[64] 
 
56) Vishnu A. Kangralkarl. , et al., (2010)   has    investigated    to elucidate 
hepatoprotective activity of Methanolic Fruit extract of Feronia elephantum in  
paracetamol induced liver damage in Wistar rats. Liver damage was produced 
by paracetamol (2gm/kg,p.o.) in 1% CMC. The Plant extract (200mg/kg, p.o.) 
was administered every 24 hrs for seven days, while standard group received 
N-acetyl l-cystine . At the end of the study the marker enzymes in serum were 
analysed. The methanolic extract showed significant hepatoprotective activity 
and efficacy of extract was almost comparable to that of N-acetyl l-cystine .  
[65] 
 
57) Vetrivel Rajan ,  et al  ., (2009)  has  studied the hepatoprotective effects of 
Cassia tora against carbon tetra chloride induced liver damage in albino rats. 
The efficacy of the treatment was estimated by the serum level marker 
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enzymes: serum glutamatie oxaloacetic transaminase, serum glumate pyruvate 
transaminase and lactate dehydrogenase. The treatment so includes the 
estimation of enzymatic antioxidants superoxide dismutase, glutathione 
peroxidase, glutathione-S transferase and catalase, non-enzymatic 
antioxidants: vitamin C and vitamin E. The results of this study   increase of 
marker enzymes in induced rats and decreased level in cassia tora treated ones. 
Furthermore, the level of enzymatic and non-enzymatic antioxidant level was 
elevated in treated rats compared to induced ones. 
[66]
 
 
58) Al-Qarawi, et al., (2001) has evaluated the aqueous extract of the Adansonia 
digitata (Linn.) pulp was tested for hepatoprotective activity against chemical 
toxicity with CCL4 in rats. The aqueous extract exhibited significant 
hepatoprotectiveactivity  .  
[67] 
 
59) Manokaran, et al., (2008) conducted to evaluate the hepatoprotective activity 
of hydroalcoholic extract of Aerva lanata against paracetamol induced liver 
damage in rats. The hydro alcoholic extract of Aerva lanata (600mg/kg) was 
administered orally to the animals with hepatotoxicity induced by paracetamol 
(3gm/kg). Silymarin (25mg/kg) was given as reference standard. All the test 
drugs were administered orally by suspending in 0.5% Carboxy methyl 
cellulose solution. The plant extract was effective in protecting the liver 
against the injury induced by paracetamol in rats. This was evident from 
significant reduction in serum enzymes alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphatase (ALP) and bilirubin . 
It was concluded from the result that the hydro alcoholic extract of Aerva 
lanata possesses hepatoprotective activity against paracetamol induced 
hepatotoxicity in rats. 
[68]
 
 
60) Iniaghe, et al.,   (2008) of simultaneous treatment of CCl4 (i.p) with 60 mg/kg 
(p.o) of aqueous extract of leaves of Acalypha racemosa on rat liver was 
evaluated. Analysis of serum ALT and AST activities with those of the 
concentrations of albumin, total protein, un conjugated and total bilirubin were 
carried out.  The malondialdehyde (MDA) content of liver was determined to 
investigate a probable mechanism of action of the extract. Administration of 
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CCl4 alone to rats significantly increased total bilirubin concentration and the 
activities of ALT and AST (p < 0.05) in the serum while it significantly 
reduced (p < 0.05) serum total protein and albumin concentrations when 
compared with controls which received distilled water (p.o). Also it 
significantly increased (p < 0.05) liver MDA content when compared with 
control. However, simultaneous treatment of CCl4 with 60 mg/kg of the 
aqueous extract significantly reversed (p < 0.05) these changes. Results of 
MDA content of liver homogenates suggest that a probable mechanism of 
action of the extract is anti oxidation. Histopathological studies were carried 
out on the liver to confirm the observed change. 
[69]
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AIMS AND OBJECTIVES 
 
 
The objectives of the present investigation are:  
 
1) To prepare hydroalcoholic extract of Plumbago zeylanica L. (HAEPZ) and to 
carry out preliminary phytochemical screening of the extract. 
2) To study the anti-inflammatory activity of HAEPZ. 
3) To study the analgesic activity of HAEPZ. 
4) To study the anti-arthritic activity of HAEPZ. 
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PLAN OF WORK 
 
 
In order to achieve the objectives, following animal models were selected. 
 
1. Anti-inflammatory Activity:  
      The anti-inflammatory activity was evaluated using following animal models: 
 Carrageenan induced rat paw edema. 
 Cotton pellet granuloma. 
 
2. Analgesic Activity: 
The analgesic activity was evaluated using following animal models: 
 Formalin induced hyperalgesia. 
 Hot Plate. 
 Tail flick. 
 Acetic acid induced writhing. 
 
3. Anti-arthritic Activity: 
The anti-arthritic activity was evaluated by FCA (Freund’s Complete 
Adjuvant) induced arthritis in rats. 
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PLANT PROFILE 
 
 
Fig.No:1 
Plumbago zeylanica Linn. 
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SCIENTIFIC CLASSIFICATION
 
 
Kingdom : Plantae 
 
Unranked : Angiosperms 
 
Unranked : Eudicots 
 
Unranked : Core eudicots 
 
Order  : Caryophyllates 
 
Family  : Plumbaginaceae 
 
Genus  : Plumbago 
 
Species :           Plumbago zeylanica 
 
Synonyms : Plumbagoscandens 
 
 
REGIONAL NAMES 
 
English  :  Lead wort, Ceylon lead wort 
Hindi  :  Chira,Chitra. 
Gujrati  :  Chitrakmula. 
Malayalam :  Vellakeduveli. 
Kannada :  Chitrakmula,Bilichitrama/ula 
Punjabi  :  Chitra 
Bengali  :  Chita 
Tamil  :  Kodiveli, Chitramoolam 
Telugu  :  Chitramulam 
Nepali              :             Chitu 
Samskrit   :           Chitraka 
Arabia              :       Shitaraj, Ensain,  Enkin 
Assamese        :     Agiyichit, Agmachit ,Bogaagechita 
Bengali           :      Chita   
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Burma                :   Kanchopphiju 
Chinese              :    PaiHuaT’eng 
French              :     Dentalaire 
German          :    Bleiwurz 
Indonesia         :   Ceraka 
Kashmiri        :   Chitra 
Manipuri        :   Chitraka 
Oriya            :  Chitamula 
Phillipine     :   Sagdikit 
Swahili        :  Sanza 
Tswana       :    Mosikomabe 
Urdu            :    Cheetab 
 
PHYTOCHEMISTRY 
 
Flower: Flowers contain plumbagin, zeylanone, and glucose.  
Leaves: Leaves contain plumbagin, chitanone.  
Stem: Stem contain plumbagin, zeylanone, isozeylanone, sitosterol, stigmasterol, 
campesterol, and dihydroflavinol-plumbaginol.  
Roots: The root bark of P. zeylanica contains plumbagin. The root yield new 
pigment, viz, 3-chloroplumbagin, 3, 3- biplumbagin, binaphthoquinone identify as 3', 
6'- biplumbagin, and four other pigments identify as isozeylanone, zeylanone, 
elliptinone, and droserone 2, 3. Two plumbagic acid glucosides; 3’o-beta-
glucopyranosyl plumbagic acid and 3’-o-beta- glucopyranosylplumbagic acid methyl 
ester along with five naphthaquinones (plumbagin, chitranone, maritinone, elliptinone 
and isoshinanolone), and five coumarins (seselin, methoxyseselin, suberosine, 
xanthyletin and xanthoxyletin) were isolated from the roots.
 
Fruit: It contains plumbagin, glucopyranoside, and sitosterol.  
Seeds: Seeds contain plumbagin.  
Dr. D. Stephen,                                           The American College, 
Lecturer                                        Madurai-2 
Department of Botany             
 
 
 
CERTIFICATE 
 
 
 
This is to certify that the plant specimen brought to me 
by Mr. C. YOGESH PRABHU, II
nd
 year M. Pharm 
(Pharmacology) Student of K. M. College of Pharmacy, 
Madurai has been identified as Plumbago zeylanica Linn 
belonging to the family Plumbaginaceae.  
 
 
 
 
Date ; 20/08/2014 
Madurai 
Tamil nadu 
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MATERIALS AND METHODS 
Materials  
Animals 
 
Species: Swiss albino mice and Wistar rats of either sex were obtained from 
the K. M. College of Pharmacy, Madurai an approved breeder of laboratory animals. 
 Age: Adult – mice and rats. 
 Weight: Swiss albino mice- 20-30g, Wistar rats - 180-200g 
 
  Housing conditions:  
Animals were maintained at a temperature of 25±1°C and relative humidity of 
45 to 55% under 12-h light:12-h dark cycle. The animals had free access to food 
pellets and water was available ad libitum. They were housed individually in the 
polypropylene cages after wounding. 
 
  Research protocol approval: 
  The experimental protocol was approved by the Institutional Animal Ethics 
Committee (IAEC) constituted in accordance with the rules and guidelines of the 
Committee for the Purpose of Control and Supervision on Experimental Animals 
(CPCSEA), India (research protocol approval number no: IAEC/KMCP/129/2014-
2015). 
 
Drugs and chemicals  
Chemicals: 
 
 Carrageenan (Sigma-Aldrich, St.Louis MO, USA)  
 Freunds complete adjuvant (Sigma-Aldrich, St.Louis MO, USA)  
 Acetic acid (Pure Chem. Ltd, Pune, India)  
 Pentazocine (Fortwin) Ranbaxy Pharmaceuticals. 
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 Anaesthetic ether (Batch No. 300) was purchased from TKM Pharma, 
Hyderabad. Ethanol (GB67890) Batch No. 080618 manufactured by Changshu 
Chemical.Formalin (Merck) 
 Diclofenac (gift sample from Symed labs, Hyderabad). 
 Indomethacin (gift sample from Symed labs, Hyderabad). 
         -Tetraethoxypropane, Crystalline beef liver catalase, reduced glutathione, 
5 5’-dithiobis (2-nitrobenzoic acid), bovine serum albumin, were gift samples 
obtained from Department of Pharmaceutical Technology, M.S. University of 
Baroda, India. 
 Thiobarbituric acid, tris buffer, sucrose, urethane (Hi-Media Laboratories Pvt. 
Ltd., Mumbai, India).  
 Trichloroacetic acid, citric acid monohydrate, sodium nitrate, copper sulphate, 
sodium potassium tartarate, methanol, ethanol, ethylene diamine tetra acetic acid 
disodium salt and Folin’s phenol reagent (S.D. Fine Chemicals  Mumbai  India). 
 Sodium hydroxide, sodium carbonate, magnesium chloride, sodium carbonate, 
sodium bicarbonate, Potassium chloride, calcium chloride, disodium hydrogen 
orthophosphate, potassium dihydrogen orthophosphate, carbon tetrachloride, 
chloroform, ether, hydrochloric acid and conc. Sulphuric acid (Qualigens 
Chemicals Ltd., Mumbai, India) 
 
PHYTOCHEMICAL AND QUALITATIVE ANALYSIS  
 
Extraction of the Plant Material 
 
Collection of plant material 
Fresh plant of plumbago zeylanica Linn was collected from Alagari Hills, 
Madurai, Tamil Nadu. The plant specimen was authenticated by Dr.D.Stephen, 
Lecturer, Dept of Botany, The American College, Madurai, Tamil Nadu. 
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Preperation of Plant Extract 
 
Materials 
 Soxhlet apparatus, 
 Pet. Ether, Chloroform, Ethanol, Distilled water and 
 Shade dried plant of Plumbago zeylanica. 
Method 
The whole plant of Plumbago zeylanica was dried in the shade. Then the 
shade dried plants were powdered to get coarse powder and about 500gms of dried 
powder of Plumbago zeylanica were soaked in extractor and macerated for 30 hr with 
petroleum ether, followed by chloroform. Then it is extracted with water: ethanol by 
continuous hot percolation technique using Soxhlet apparatus for 72hrs. Crude extract 
were distilled under vaccum condition. After concentration, the hydro alcohol extract 
gives brownish residue which weigh about 7.2gms. The extract was used for 
experimentation.      
Table No. 1 
PHYTOCHEMICAL INVESTIGATION OF  
EXTRACT OF PLUMBAGO ZEYLANICA L. 
 
NAME OF THE TEST RESULT 
TEST FOR CARDIAC GLYCOSIDES 
 
Legals test 
 
Kedde’s test 
 
 
+ ve 
 
+ ve 
TEST FOR ALKALOIDS 
 
Dragendoff’s test 
 
Mayers test 
 
Wagners test 
 
 
+ ve 
 
+ ve 
 
+ ve 
TEST FOR TANNINS 
 
Ferric chloride test 
 
 
+ ve 
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TEST FOR STEROIDS 
 
Lieberman-Burchard’s test 
 
Salkowski’s test 
 
 
+ ve 
 
-ve 
TEST FOR FLAVONOIDS 
 
Ferric chloride test 
 
Lead acetate test 
 
Sodium hydroxide test 
 
 
+ ve 
 
+ ve 
 
+ ve 
TEST FOR SAPONINS 
 
Frothing test 
 
 
+ ve 
TEST FOR ANTHRAQUINONES 
 
Brontragers test 
 
 
+ve 
TEST FOR PHOBATINNINS 
 
+ve 
TEST FOR CARBOHYDRATES +ve 
 
 
 
Statistical Analysis 
 
  The Arithmetic mean ± SEM values were calculated for each experiment. The    
statistical analyses were carried out with help of Graph pad Prism 5. 
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PHARMACOLOGICAL EVALUATION 
Anti inflammatory activity 
 
  Effect of hydroalcoholic extract of Plumbago zeylanica L. on Carrageenan 
induced rat paw oedema (70) Winter et al., 1962) 
The male Wistar Rat of 150-200gm Carrageenan induced rat paw oedema is a 
golden model for screening of acute of anti-inflammatory activity of test compound.  
 
The animals were divided into 5 groups with 6 rats per group as follows- 
Group I –    Healthy Control 
Group II -   Vehicle (0.1 % CMC, 10 ml/kg) 
Group III -  Diclofenac (10 mg/kg) 
Group IV - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group V-   Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.) 
 
0.1 ml of 1% carrageenan solution was injected into the left hind paw of the 
rat. The pre treatment time was 1 hour before carrageenan injection. The paw volume 
was recorded at 0, 1, 2, 3, 4 and 24 hrs by using plethysmometer (UGO Basile 7140).  
Percentage inhibition of edema was calculated at different hours. The percentage 
inhibition of edema in the various treated groups was then calculated by using the 
formula, 
% Inhibition = (1 – Vt / Vc) x 100 
Where, Vt is change in paw volume in the drug treated group  
                Vc is change in paw volume in the control group. 
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 Effect of hydroalcoholic extract of Plumbago zeylanica L. against cotton pellet 
granuloma (71) Swingle  and Shideman, 1972) 
 
Subcutaneous implantation of pellets of compressed cotton provokes foreign 
body granuloma. The rats were divided randomly into 4 different groups: 
 
Group I -   Vehicle (0.5 % CMC, 10 ml/kg) 
Group II -  Diclofenac (10 mg/kg) 
Group III - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group IV-  Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.) 
 
Cotton rolls were cut and made into pellets weighing 20 mg each and 
sterilized in an autoclave at 121°C for 30 min. Four individual pellets were inserted in 
each ether anesthetized animal by making small subcutaneous incisions in both axillae 
and groin regions. The incisions were sutured by sterile catgut. After recovery from 
anesthesia; the animals were treated orally for 7 days. On eighth day animals were 
sacrificed, and the granulomas were freed from extraneous tissue, dried overnight at 
55°c and weighed to obtain constant weight. The average weight of the pellets of the 
control group as well as of the test group was calculated. The percent change of 
granuloma weight relative to vehicle control group was determined. 
 
The percentage inhibition of increase in weight of the cotton pellet was calculated as 
follows: 
%Inhibition = (1-(Wt/Wc)) x 100 
    Wt = Difference in pellet weight of drug treated group 
Wc = Difference in pellet weight of control group 
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Analgesic Activity: 
 
   Effect of hydroalcoholic extract of Plumbago zeylanica L. on hot plate test in 
mice: 
Male Swiss albino mice (20-25 gm) were divided into four groups containing 
6 animals in each group. 
Group I   -   Vehicle (0.1 % CMC, 10 ml/kg) 
Group II  -  Pentazocine (20 mg/kg i.p.) 
Group III - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group IV -Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.) 
 
                                                                                
                                                                                 
                                                                                  
either licking of the fore or hind paws, shaking or jumping off from the surface was 
recorded as response latency. Mice with basal latencies of more than 20s were 
eliminated from the study. The testing of response latencies were noted at 0, 30, 60, 
90, 120, 150, 180 and 210 min after treatment. The cut off time for hot plate latencies 
was set at 15s. 
 
 Effect of hydroalcoholic extract of Plumbago zeylanica L. on formalin 
induced hyperalgesia in mice (72) Murray et al., 1988) : 
Male Swiss albino mice (20-25 gm) were divided into four groups containing 
6 animals in each group. 
 
Group I  -  Vehicle (0.1 % CMC, 10 ml/kg) 
Group II  - Pentazocine (20 mg/kg i.p.) 
Group III - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group IV - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.) 
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The formalin test was carried out according to the method of (73) Sugimoto et 
al. (1986) and (74) Ilja Arts et al. (2005). 60 min after the oral or 30 min after intra-
peritoneal administration           2 μ      %                                       
injected to the right hind paw of mice, and the nociceptive behavior was recorded for 
a period of 60 min. The total time (in = seconds) of the nociceptive behavior (licking, 
biting, lifting and shaking) observed after the injection of formalin was measured as 
an indicator of nociceptive behavior. The first period (early phase) was 0–10 min after 
the formalin injection, and the second period (late phase) was 15–30 min after the 
injection. These phases represented neurogenic and inflammatory pain responses, 
respectively (75) Hu WJ et al, 1987). 
 
   Effect of hydroalcoholic extract of Plumbago zeylanica L. on  nociceptive tail 
flick reflex: 
The tail flick test (76) D’Amour and Smith, 1941) is based on tail withdrawal 
in response to heat from a light beam focused on the ventral tail surface. Tail Flick 
apparatus (UGO BASILE, Biological Research Apparatus 21025 Camerio VA, Italy) 
was used. Response latency was the time from application of the light until the tail 
flicked. The cut off time was 15 seconds. Wistar rats (180-200 g) of either sex were 
divided into four groups: 
 
Group I -    Vehicle (0.1 % CMC, 10 ml/kg) 
Group II -   Pentazocine (20 mg/kg i.p.) 
Group III - Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group IV- Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.). 
 
Respective treatment was given to the groups and tail flick latencies of 
animals was determined at 0, 30, 60, 90, 180 and 210 min after the drug 
administration.  
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Anti-arthritic Activity 
 
  Effect of hydroalcoholic extract of Plumbago zeylanica L. on FCA induced 
Arthritis 
Wistar rats (female) weighing 175 to 200 g were divided into five groups of 6 
rats each. 
 
Group I –  Healthy Control 
Group II - Vehicle (0.1 % CMC, 10 ml/kg) 
Group III - Indomethacin (10 mg/kg) 
Group IV-  Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (200 mg/kg p.o.) 
Group V- Hydroalcoholic extract of Plumbago zeylanica (HAEPZ) (400 mg/kg p.o.). 
 
                      “            ”     “           ”   j v              
have gained wide usage for assessing a drug potential for antiarthritic activity. In 
present investigation we have selected the therapeutic schedule for evaluating the anti 
arthritic effect of the test compound. Wistar rats with an initial body weight of 175-
200 gm were used. On day 0, FCA (complete fraction of Mycobacterium butyricum 
suspended in oil; Sigma Chemical Co., USA) was injected (0.1 ml) into the sub 
plantar region of the left hind paw. One hundred percent of the animals developed 
arthritis. Everyday animals were inspected, by examining the affected paw, body 
                     ’                  I                                 j          
FCA produced a pronounced local edema after a few hours with a progressive 
increase reaching its maximum on the 12
th
 day after inoculation. Dosing with the test 
compounds was started from day 12 to day 28. 
 
Following parameters were determined: 
 
1. In-vivo parameters 
In-vivo parameters were determined on day 0, 3, 7, 10, 12, 14, 17, 21, 24 and 
28. The parameters are paw volume, WBC Count, Joint Diameter, Arthritis Score, 
Body weight, Pain threshold (Randall Sellito), Mechanical Withdrawal Threshold 
(Von Frey Hair), Paw withdrawal Latency. 
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2. Biochemical Parameters 
On day 28 blood was withdrawn by reto-orbital puncture and serum was used 
for estimation of Albumin Acid phosphatase and Alkaline Phosphatase. 
 
3. Tissue Estimation: 
On day 28 liver tissue was used for the estimation of SOD, MDA, GSH and 
total protein. 
 
4. Histopatholgy of tibio tarsal joint was performed on Day 28. 
 
 Paw Volume was determined 
 WBC count was measured using Neubauer counting chamber. 
 Joint diameter was measured by the use of digital vernier calipers. 
 Arthritis Score: 
The morphological feature of the arthritis like redness, swelling and erythma 
was monitored daily by set visual criteria. The following scoring system was used: 
 
Normal paw = 0  
Mild swelling and erythema of digits  = 1 
Swelling and erythema of the digits =  2  
Severe swelling and erythema = 3 
Gross deformity and inability to use the limb = 4 
 
 Pain Threshold (g) was measured using Randall sellito. 
 Paw withdrawal latency was measured using IR beam using tail flick apparatus.  
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RESULTS 
Anti-inflammatory Study: 
Carrageenan induced rat paw edema: 
The paw volume was elevated in carrageenan control when compared to 
normal control (p<0.001). Treatment with hydroalcoholic extract of Plumbago 
zeylanica  at a dose of 200 mg/kg and 400 mg/kg exhibited a significant decrease in 
paw volume at 3
rd
, 4
th
 and 24
th
 h. HAEPZ (400mg/kg) showed significant (p<0.001) 
decrease in paw volume at 3
rd
 h  whereas HAEPZ (200mg/kg) did not show any 
significant decrease in paw volume at 3h. Plumbago zeylanica   (200mg/kg) showed 
significant (p<0.01) decrease in paw volume at 4
th 
h. Diclofenac (10 mg/kg) exhibited 
a significant reduction in paw volume at 2
nd
 h (p<0.01) and 3
rd
, 4th and 24
th
 h 
(p<0.001).  
Table No. 2: Effect of hydroalcoholic extract of Plumbago zeylanica L. on change 
in paw volume in carrageenan induced paw edema in female wistar rats 
Treatment Change in paw volume (ml)  
1 h 2 h 3 h 4 h 24 h 
Healthy  
Control 
0.07 
±0.00 
0.06 
±0.01 
0.07 
±0.01 
0.06 
±0.01 
0.07 
±0.00 
Carrageenan 
Control 
0.55 
±0.04
#
 
0.82 
±0.03
#
 
1.61 
±0.09
#
 
1.96 
±0.04
#
 
0.55 
±0.04
#
 
Diclofenac 
 (10 mg/kg) 
0.49 
±0.04 
0.65 
±0.02** 
0.67 
±0.04*** 
0.45 
±0.03*** 
0.49 
±0.04*** 
HAEPZ 
(200 mg/kg) 
0.47 
±0.01 
0.74 
±0.04 
1.47 
±0.05 
1.60 
±0.04** 
0.47 
±0.01** 
HAEPZ  
(400 mg/kg) 
0.48 
±0.01 
0.66 
±0.02 
0.72 
±0.06*** 
0.67 
±0.06*** 
0.48 
±0.01*** 
 
Values are expressed as mean ± SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Carrageenan Control  
#p<0.001 when compared to Healthy Control 
 
The percentage inhibition of change in paw volume of HAEPZ (200mg/kg) 
and 400mg/kg was found to be 23.16% and 41.33% respectively at 3h .However the 
maximum percentage inhibition was found to be at 4h. The percentage inhibition of 
Diclofenac (10 mg/kg) was found to be 26.86%, 49.23% and 47.73% at 2
nd
, 3
rd
 & 
24
th
h respectively.  
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Cotton pellet granuloma 
 
The dry weight of cotton pellet in Diclofenac (4 mg/kg) group after 7 days of 
treatment was 167.3±7.10 mg as compared to control group (167.3±7.10 mg) 
(p<0.001). Treatment with HAEPZ (200 mg/kg) & HAEPZ (400 mg/kg) resulted in 
reduced granuloma formation as compared to control group (p<0.01 and p<0.001 
respectively).  The percentage inhibition of granuloma formation in HAEPZ 200 and 
HAEPZ 400 mg/kg was found to be 27.76% and 35.65% respectively. 
Table No. 3: Effect of hydroalcoholic extract of Plumbago zeylanica. L. on dry 
weight (mg) in Cotton pellet granuloma in female wistar rats. 
 
Treatment Mean dry weight of 
cotton pellet (mg)
1 
Percentage 
Inhibition (%) 
Control 163.3±7.10 -- 
Diclofenac (4 mg/kg) 78.14±3.40*** 41.75 
HAEPZ(200 mg/kg) 105.4±3.66** 27.76 
HAEPZ(400 mg/kg) 90.58±3.67*** 35.65 
 
1
Values are expressed as mean±SEM of 6 values 
1One way ANOVA followed by Dunnet’s post-test  
**p<0.01, ***p<0.001 when compared to Control 
 
 
Analgesic Study 
 
Acetic Acid induced writhing: 
 
The number of writhings in the animals treated with HAEPZ (200 mg/kg) and 
HAEPZ (400mg/kg) was significantly lower when compared to acetic acid control 
group (p<0.05,p<0.01,p<0.001 respectively). Diclofenac (10 mg/kg) significantly 
(p<0.001) reduced the no. of writhings when compared to acetic acid control group. 
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Table No. 4: Effect of hydroalcoholic extract of Plumbago zeylanica. L. on no. of 
writhings in Acetic acid induced writhing in mice 
Treatment No. of writhings 
Control 49.67±2.21 
Diclofenac (10 mg/kg) 4.833±1.13*** 
HAEPZ (200 mg/kg) 38.17±2.38** 
HAEPZ (400 mg/kg) 25.33±2.52*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Acetic acid Control 
 
Formalin induced hyperalgesia: 
 
Pentazocine reduced the duration of paw licking significantly in phase 1 and 
phase2 when compared to control group (p<0.001). HAEPZ did not show significant 
effect in phase1 of formalin induced hyperalgesia. However HAEPZ 200mg/kg and 
400mg/kg showed dose dependent reduction (p<0.05, p<0.01, p<0.001 respectively) 
in duration of paw licking in phase 2 of formalin induced hyperalgesia. 
 
Table No. 5: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
duration of paw licking (sec) in Formalin induced hyperalgesia (Phase I) in mice. 
 
Treatment Duration of paw licking (sec) 
Control 281.7±9.45 
Pentazocine (20 mg/kg) 63.83±5.51*** 
HAEPZ(200 mg/kg) 291.0±8.49 
HAEPZ(400 mg/kg) 272.5±10.47 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
***p<0.001 when compared to Normal Control 
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Table No. 6: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
duration of paw licking (sec) in Formalin induced hyperalgesia (Phase II) in mice 
 
Treatment Duration of paw licking (sec) 
Control 173.2±6.19 
Diclofenac (10 mg/kg) 33.33±3.96*** 
HAEPZ(200 mg/kg) 130.7±5.72** 
HAEPZ(400 mg/kg) 62.17±4.72*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Control. 
 
Hot plate : 
Table No. 7: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
Latency (sec) latency in Eddy’s Hot plate in mice 
 
Treatment Latency (sec) 
0 min 30 min 60 min 90 min 120 min  150 min 180 min 
Control 3.41 
±0.41 
3.23 
±0.30 
3.51 
±0.17 
3.31 
±0.23 
3.76 
±0.34 
3.50 
±0.30 
3.33 
±0.21 
Pentazocine 
(20 mg/kg) 
3.48 
±0.31 
5.61 
±0.29*** 
8.88 
±0.30*** 
3.91 
±0.21 
4.63 
±0.47 
3.55 
±0.30 
3.23 
±0.21 
HAEPZ(200 
mg/kg) 
3.43 
±0.41 
3.55 
±0.17 
3.133 
±0.14 
4.28 
±0.32 
3.60 
±0.24 
3.00 
±0.13 
3.38 
±0.16 
HAEPZ(400 
mg/kg) 
3.43 
±0.41 
3.61 
±0.13 
3.40 
±0.23 
4.36 
±0.32 
3.60 
±0.24 
3.05 
±0.17 
3.38 
±0.16 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test 
***p<0.001 when compared to Normal Control 
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Tail Flick Assay: 
 
HAEPZ did not inhibit thermal hyperalgesia significantly at any of the doses when 
compared to control group. Pentazocine (20mg/kg ip) significantly inhibited thermal 
hyperalgesia at 30 & 60 min (p<0.001). 
 
Table No. 8: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
Latency of tail flick in Tail Flick in female wistar rats. 
Treatment Latency of tail flick (sec) 
0 min 30 min 60 min 90 min 120 min  150 min 180 min 210 min 
Control 4.17 
±0.40 
4.17 
±0.30 
4.33 
±0.33 
4.33 
±0.42 
4.35 
±0.50 
4.16 
±0.30 
3.16 
±0.40 
4.00 
±0.36 
Pentazocine 
(20 mg/kg) 
4.16 
±0.40 
4.16 
±0.30*** 
4.33 
±0.33*** 
4.33 
±0.42 
3.50 
±0.50 
4.16 
±0.30 
3.16 
±0.40 
4.00 
±0.36 
HAEPZ(200 
mg/kg) 
4.16 
±0.60 
6.16 
±0.65 
6.50 
±0.42 
5.50 
±0.42 
4.66 
±0.21 
4.66 
±0.33 
4.16 
±0.30 
4.33 
±0.49 
HAEPZ 
(400 mg/kg) 
5.00 
±0.96 
4.00 
±0.57 
4.00 
±0.57 
4.16 
±0.65 
5.16 
±0.60 
6.16 
±0.47 
5.00 
±0.57 
4.00 
±0.36 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test 
***p<0.001 when compared to Normal Control. 
 
 
Anti-arthritic Study:  
 
Change in paw volume 
 
Change in paw volume of the injected paw of animals of all the treatment group of 
animals showed a typical biphasic response with an initial peak at 4
th
 day and 12
th
day 
post injection of FCA into the sub-plantar region of the rat. Indomethacin (10mg/kg) 
caused significant (p<0.001) inhibition the elevation of the paw volume recorded at 
14
th
, 17
th
, 21
st
, 24
th
 and 28
th 
day when compared to arthritic control. On 17
th
 day 
HAEPZ (200mg/kg) and HAEPZ (400mg/kg) inhibited the rise in paw volume 
(p<0.01,p<0.001 respectively). Thus HAEPZ resulted in inhibition of paw volume in 
dose dependent manner. 
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Table No. 9: Effect of hydroalcoholic extract of Plumbago zeylanica L. on change in paw volume (mL) in FCA induced arthritis in 
female wistar rats. 
 
 
Treatment Change in paw volume (mL) 
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
0.00 
±0.00 
0.04 
±0.07 
0.04 
±0.08 
0.03 
±0.04 
0.02 
±0.06 
0.04 
±0.12 
0.05 
±0.009 
0.05 
±0.05 
0.05 
±0.02 
0.05 
±0.06 
Arthritic 
Control 
0.00 
±0.00 
2.92 
±0.12
# 
2.38 
±0.03
# 
2.92 
±0.12
# 
3.03 
±0.11
# 
2.99 
±0.11
# 
2.92 
±0.11
# 
2.88 
±0.11
# 
2.83 
±0.09
# 
2.50 
±0.06
# 
Indomethaci
n  
(10 mg/kg) 
0.00 
±0.00 
2.93 
±0.07 
2.63 
±0.07 
2.90 
±0.03 
3.09 
±0.05 
2.45 
±0.12*** 
1.75 
±0.09*** 
1.19 
±0.05*** 
0.74 
±0.02*** 
0.26 
±0.05*** 
HAEPZ  
(200 mg/Kg) 
0.00 
±0.00 
2.92 
±0.03 
2.45 
±0.10 
2.84 
±0.07 
3.04 
±0.01 
2.92 
±0.01** 
2.57 
±0.05** 
2.30 
±0.10** 
1.86 
±0.08** 
1.64 
±0.10** 
HAEPZ  
(400 mg/kg) 
0.00 
±0.00 
2.62 
±0.10 
2.33 
±0.04 
2.60 
±0.09 
3.03 
±0.04 
2.66 
±0.04 
2.18 
±0.04** 
1.64 
±0.05** 
1.00 
±0.04** 
0.87 
±0.11** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control  
#p<0.001 when compared to Healthy Control 
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Table No. 10: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
Percentage Inhibtion paw vloume in FCA induced arthritis in female wistar rats. 
Treatment Percentage Inhibition 
0 
day 
4 
day 
7 
day 
10 
day 
12 
day 
14 
day 
17 
day 
21 
day 
24 
day 
28 
day 
Healthy 
Control 
-- -- -- -- -- -- -- -- -- -- 
Arthritic 
Control 
-- -- -- -- -- -- -- -- -- -- 
Indomethacin 
(10 mg/kg) 
-- -- -- -- -- 34.24 35.83 45.83 47.5 45.75 
HAEPZ 
(200 mg/kg) 
-- -- -- -- -- 17.16 23.33 33.33 35.17 33.33 
HAEPZ  
(400 mg/kg) 
-- -- -- -- -- 18.45 36.50 41.50 42.33 41.50 
 
The percentage inhibition of paw volume in animal treated with HAEPZ 400 
mg/kg  was found to be equal to 30,36.5,41.5,42.33,43.57 respectively on 14
th
 , 17
th
 
,21
st
 , 24
th
 & 28
th 
day. The percentage inhibition in animal treated with HAEPZ 200 
mg/kg was found to be equal to 17.17, 23.33, 33.33, 35.17 & 32.86 respectively on 
14
th
, 17
th
, 21st, 24
th
 & 28
th 
day. Hence HAEPZ was able to inhibit the rise in paw 
volume in a dose dependant manner during the treatment period starting from 12
th
 day 
after injection of FCA. 
 
WBC Count 
 
A Change in WBC count of the injected paw of animal of all the treatment 
group of animals exhibited a typical biphasic response with an initial peak at 4
th
 day 
and on 14
th
 day. Post injection of FCA into the sub-plantar region of the rat. WBC 
Count was significantly elevated (p<0.001) in arthritic control group when compared 
to normal control. HAEPZ (200 mg/Kg) and HAEPZ (400 mg/Kg were able to inhibit 
WBC count in dose dependent (p<0.01 and p<0.001) manner starting from 17
th
 day. 
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Table No. 11: Effect of hydroalcoholic extract of Plumbago zeylanica L. on WBC Count in FCA induced arthritis in female wistar rats. 
 
Treatment WBC Count  
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
10298.83
±132.27 
10340.83
±124.36 
10300.67
±123.88 
10302.00
±117.51 
10269.67
±101.36 
10297.33 
±121.68 
10241.00 
±77.40 
10300.33 
±90.88 
10222.30 
±66.83 
10251.83 
±68.42 
Arthritic 
Control 
10700.00
±230.94 
16003.33
±409.33
# 
13166.67
±362.09
# 
16003.33
±409.33
# 
19616.67
±162.10
# 
19516.67 
±160.12
# 
19150.00 
±164.82
# 
18600.00 
±175.11
# 
17983.33 
±199.02
# 
17700.00 
±177.01
# 
Indomethacin 
(10 mg/kg) 
10757.50
±210.03 
16087.50
±611.71 
13315.83
±246.34 
16087.50
±611.70 
19506.17
±219.24 
15764.83 
±242.47*** 
14850.33 
±223.30*** 
13913.33 
±278.40*** 
13310.67 
±288.69*** 
11891.00 
±259.59*** 
HAEPZ 
(200 mg/kg) 
10838.67
±226.64 
15492.33
±143.74 
13267.33
±316.55 
15492.33
±143.74 
19679.00
±175.38 
18861.17 
±187.97 
17891.17 
±427.31** 
17221.00 
±392.60** 
16573.67 
±365.32** 
16414.50 
±329.83** 
HAEPZ (400 
mg/kg) 
10747.17
0±112.21 
15380.500
±180.30 
13307.000
±320.57 
15380.500
±180.30 
19658.170
±179.69 
19083.500 
±143.41 
17620.670 
±258.73*** 
16723.170 
±223.24*** 
15685.170 
±206.75*** 
15183.670 
±235.28*** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control   
#p<0.001  when compared to Healthy  Control. 
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Table No. 12: Effect of hydroalcoholic extract of Plumbago zeylanica L. on mechanical withdrawal threshold (g) in FCA induced 
arthritis in female rats 
Treatment Mechanical Withdrawal Threshhold Mean ± SEM 
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
77.83±2.70 79.66±1.85 80.00±1.96 78.16±2.37 79.00±2.20 79.33±2.55 77.83 
±2.00 
78.33 
±2.27 
79.83 
±2.37 
78.66 
±1.85 
Arthritic 
Control 
75.66±1.56 29.00±0.73
# 
38.83±1.42
# 
32.16±0.87
# 
23.33±1.74
# 
24.00±1.94
# 
21.16 
±1.83
# 
21.66 
±1.66
# 
24.59 
±1.85
# 
28.00 
±1.63
# 
Indomethacin 
(10 mg/Kg) 
74.16±2.76 33.33±2.10 39.66±1.99 34.50±1.56 23.16±2.08 41.66±3.01*** 49.83 
±2.24*** 
56.66 
±1.85*** 
61.00 
±2.22*** 
70.16 
±1.30*** 
HAEPZ  
(200 mg/Kg) 
72.33±2.72 34.16±2.52 50.83±2.19 37.33±2.38 23.83±2.21 25.83±2.18 31.50 
±2.06** 
36.50 
±2.07** 
41.83 
±2.31** 
46.00 
±2.11** 
HAEPZ  
(400 mg/Kg) 
76.66±3.98 33.66±1.90 47.66±1.45 41.66±1.99 23.50±1.99 27.33±2.02 41.16 
±1.92*** 
47.83 
±1.30*** 
51.33 
±1.68*** 
57.33 
±2.33*** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control  
#p<0.001 when compared to Healthy Control 
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Randall Sellito 
 
Pain threshold was measured by using Randall sellito analgesiometer. Pain threshold reduced in all the treatment groups upto 12
th
 day 
however after the initiation of treatment pain threshold was elevated. Indomethacin (10mg/kg) was found to significantly elevate (p<0.001) the 
pain threshold in post-treatment period (12
th
-28
th
 day) starting from 14
th
 day when compared to control group. HAEPZ (200mg/kg) and HAEPZ 
(400mg/kg) were able to elevate pain threshold when compared to control (p<0.01 and p<0.001 respectively). 
 
Table No. 13: Effect of hydroalcoholic extract of Plumbago zeylanica L. on pain threshold (g) in FCA induced arthritis in female wistar 
rats 
Treatment Pain threshold (g) 
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
280.00 
±4.47 
280.00 
±2.58 
276.66 
±4.21 
275.00 
±5.62 
278.33 
±4.01 
268.33 
±7.49 
275.00 
±5.53 
275.00 
±5.53 
270.00 
±6.83 
276.66 
±6.14 
Arthritic 
Control 
277.500 
±7.71 
166.6667 
±4.21
# 
171.6667 
±4.77
# 
166.6667 
±4.21
# 
158.3333 
±6.00
# 
155.000 
±4.28
# 
144.1667 
±3.74
# 
140.000 
±3.65
# 
131.6667 
±4.01
# 
145.000 
±5.00
# 
Indomethacin 
(10 mg/kg) 
270.00 
±5.91 
176.66 
±4.94 
185.00 
±3.41 
180.00 
±3.65 
158.33 
±4.77 
193.33 
±2.10*** 
205.00 
±5.62*** 
228.33 
±4.77*** 
241.66 
±4.77*** 
258.33 
±7.49*** 
HAEPZ (200 
mg/kg) 
283.33 
±2.47 
163.33 
±5.57 
176.66 
±3.33 
163.33 
±5.57 
150.00 
±3.65 
185.00 
±4.28 
170.00 
±7.74** 
181..66 
±3.07** 
190.00 
±2.58** 
208.33 
±3.07** 
HAERPZ (400 
mg/kg) 
275.00 
±4.28 
171.66 
±3.07 
178.33 
±3.07 
171.66 
±3.65 
150.00 
±4.28 
185.00 
±6.00 
190.00 
±4.42*** 
211.66 
±6.00*** 
216.66 
±3.33*** 
230.00 
±5.16*** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control  
#p<0.001 when compared to Healthy Control. 
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Table No. 14: Effect of hydroalcoholic extract of Plumbago zeylanica L. on Arthritis Score in FCA induced arthritis in female wistar 
rats. 
Treatment Arthritis Score  
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Arthritic 
Control 
0.00±0.00 2.50±0.22
# 
2.66±0.21
# 
3.83±0.16
# 
4.00±0.00
# 
4.00±0.00
# 
3.83±0.16
# 
3.83±0.16
# 
3.83±0.16
# 
3.83±0.16
# 
Indomethacin 
(10 mg/kg) 
0.00±0.00 2.83±0.16 2.66±0.21 3.33±0.21 4.00±0.00 1.66±0.21*** 1.33±0.33*** 0.83±0.30*** 0.66±0.21*** 0.33±0.21*** 
HAEPZ 
(200 mg/kg) 
0.00±0.00 2.83±0.16 2.83±0.21 3.33±0.21 4.00±0.00 3.16±0.16 2.50±0.22** 2.16±0.16** 1.66±0.21** 1.50±0.22** 
HAEPZ 
(400 mg/kg) 
0.00±0.00 2.66±0.00 2.33±0.21 3.66±0.21 4.00±0.00 2.50±0.22 2.16±0.16*** 1.66±0.21*** 1.16±0.16*** 0.83±0.16*** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control  
#p<0.001 when compared to Healthy Control 
 
 
 
 
 
Results 
 
74 
 
Table No. 15: Effect of hydroalcoholic extract of Plumbago zeylanica L. on paw withdrawal latency (sec) in FCA induced arthritis in 
female wistar rats 
 
Treatment Paw withdrawal latency (sec) 
0 day 4 day 7 day 10 day 12 day 14 day 17 day 21 day 24 day 28 day 
Healthy 
Control 
11.53±0.33 11.90±0.13 11.95±0.15 12.03±0.08 11.53±0.33 11.90±0.13 11.88±0.13 11.90±0.13 11.95±0.15 12.05±0.07 
Arthritic 
Control 
11.53±0.33 4.06±0.29
# 
6.01±0.24
# 
4.06±0.29
# 
2.30±0.21
# 
2.16±0.15
# 
2.06±0.12
# 
1.75±0.21
# 
1.66±0.17
# 
2.85±0.25
# 
Indomethacin  
(10 mg/Kg) 
11.60±0.23 3.78±0.09 5.58±0.26 3.78±0.09 2.53±0.17 4.93±0.41*** 6.83±0.40*** 8.80±0.23*** 9.65±0.18*** 10.65±0.19*** 
HAEPZ  
(200 mg/Kg) 
11.76±0.08 3.316±0.16 5.60±0.31 3.31±0.16 2.25±0.17 2.58±0.18 3.51±0.23** 4.21±0.25** 5.10±0.23** 6.20±0.25** 
HAEPZ  
(400 mg/Kg) 
11.90±0.04 3.38±0.19 5.80±0.25 3.38±0.19 2.26±0.15 2.83±0.23 4.38±0.23*** 5.55±0.34*** 6.51±0.38*** 8.41±0.35*** 
 
Values are expressed as mean±SEM of 6 values 
Two way ANOVA followed by Bonferroni post-test  
**p<0.01, ***p<0.001 when compared to Arthritic Control  
#p<0.001 when compared to Healthy Control 
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Paw Weight 
 
Table No. 16: Effect of hydroalcoholic extract of Plumbago zeylanica L. on Paw 
weight (g) in FCA induced arthritis in female wistar rats. 
 
Treatment Paw weight (g) 
Healthy Control 141.5±4.16 
Arthritic 
Control 
228.0±4.30 
Indomethacin (10 mg/kg) 146.8±5.00*** 
HAEPZ (200 mg/kg) 186.5±4.07*** 
HAEPZ (400 mg/kg) 166.7±4.41*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
***p<0.001 when compared to Arthritic Control. 
 
Paw weight was elevated in arthritic control group. Indomethacin (10 mg/kg) 
significantly reduced the rise in paw weight when compared to arthritic control animal 
(p<0.001). HAEPZ (50 mg/kg) did not show any significant effect on rise in paw 
weight when compared to control. HAEPZ (200 mg/kg) & HAEPZ (400 mg/kg) 
exhibited significant reduction in paw weight when compared to arthritic control 
(p<0.01&p<0.001respectively). 
 
Serum Albumin 
 
Table No. 17: Effect of hydroalcoholic extract of Plumbago zeylanica L.  on 
Serum Albumin (g/dl) in FCA induced arthritis in female wistar rats. 
 
Treatment Serum Albumin (g/dl) 
Healthy Control 4.36±0.11 
Arthritic Control 2.18±0.08*** 
Indomethacin (10 mg/kg) 4.01±0.09** 
HAEPZ (200 mg/kg) 2.83±0.19** 
HAEPZ (400 mg/kg) 3.63±0.09** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control. 
 
Serum albumin levels were reduced significantly in arthritic control group. 
Indomethacin (10 mg/kg) significantly elevated (p<0.001) serum albumin levels when 
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compared to arthritic control group HAEPZ 200 & HAEPZ 400 mg/kg exhibited dose 
dependent elevation of  serum albumin level when compared to arthritic control 
(p<0.05, p<0.01, p<0.001). 
 
Serum Alkaline Phosphatase 
 
Serum alkaline phosphatase was elevated in the arthritic control group. The 
rise in serum alkaline phosphatase was significantly inhibited (p<0.001) in the animal 
treated with Indomethacin (10 mg/kg). The rise of Serum alkaline phosphatase was 
inhibited in the dose dependent manner in animal treated with HAEPZ 200 & HAEPZ 
400 mg/kg (p<0.05, p<0.01 and p<0.001 respectively).  
Table No. 18: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
Serum Alkaline Phosphatase (U/L) in FCA induced arthritis in female wistar 
rats. 
 
Treatment Serum Alkaline Phosphatase  (U/l) 
Healthy Control 249.5±10.13 
Arthritic Control 915.7±42.80*** 
Indomethacin (10 mg/kg) 283.8±16.64*** 
HAEPZ (200 mg/kg) 787.2±17.04** 
HAEPZ (400 mg/kg) 411.0±14.26*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control 
 
Serum Acid Phosphatase 
 
Table No. 19: Effect of hydroalcoholic extract of Plumbago zeylanica L. on 
Serum Acid Phosphatase (U/l) in FCA induced arthritis in female wistar rats 
Treatment Serum Acid Phosphatase  (U/l) 
Healthy Control 3.81±0.17 
Arthritic Control 8.91±0.23*** 
Indomethacin (10 mg/kg) 3.90±0.23** 
HAEPZ (200 mg/kg) 5.71±0.38*** 
HAEPZ (400 mg/kg) 4.61±0.20*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control 
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Serum acid phosphatase was elevated in the arthritic control group. The rise in 
serum acid phosphatase significantly inhibited (p<0.001) in the animal treated with 
indomethacin (10 mg/kg) . The rise of serum acid phosphatase was inhibited in the 
dose dependent manner in animal treated with HAEPZ 200 & HAEPZ 400 mg/kg 
(p<0.05, p<0.01 & p<0.001 respectively). 
 
Oxidative Stress in Liver 
MDA 
 
Table No. 20: Effect of hydroalcoholic extract of Plumbago zeylanica L. on MDA 
(nMol/mg of protein) in FCA induced arthritis in female wistar rats. 
 
Treatment MDA (nmol/mg of protein) 
Healthy Control 2.64±0.35 
Arthritic Control 7.87±0.43 
Indomethacin (10 mg/kg) 3.61±0.23*** 
HAEPZ (200 mg/kg) 4.9±0.13** 
HAEPZ (400 mg/kg) 3.64±0.29*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control 
 
The level of MDA was elevated in the Arthritic Control group (7.87±0.43) as 
compared to the healthy control group (2.64±0.35). Indomethacin significantly 
inhibited (p<0.001) the rise of MDA. The rise of MDA was inhibited in the dose 
dependent manner in animal treated with HAEPZ 200 & HAEPZ 400 mg/kg (p<0.05, 
p<0.01 & p<0.001) respectively. 
  
 (ii) Glutathione (GSH) 
 
 The level of glutathione in the Arthritic control group was reduced to 
16.00±1.01 from the normal value of 29.58±1.24. Indomethacin (10 mg/kg) 
significantly increased (p<0.001) the level of glutathione. The glutathione levels was 
increased in the dose dependent manner in animal treated with HAEPZ 200 & 
HAEPZ 400 mg/kg (p<0.05, p<0.01 and p<0.001) respectively. 
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Table No. 21: Effect of hydroalcoholic extract of Plumbago zeylanica L. on Blood 
Glutathione (μg/mg) of protein in FCA induced arthritis in female wistar rats 
Treatment GSH  (μg/mg of protein) 
Healthy Control 29.58±1.24 
Arthritic 
Control 
16.00±1.01 
Indomethacin (10 mg/Kg) 27.15±0.74*** 
HAEPZ (200 mg/Kg) 24.11±1.31** 
HAEPZ (400 mg/Kg) 24.75±0.93*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control 
 
 
(iii) SOD : 
 
The level of SOD in the vehicle treated group was reduced to 2.65±0.34 U/l 
from the normal value of 11.23±0.35 U/l.  Indomethacin (10 mg/kg) significantly 
increased (p<0.001) the level of glutathione. The glutathione levels was increased in 
the dose dependent manner in animal treated with HAEPZ 200 & HAEPZ 400 mg/kg 
(p<0.05, p<0.01 & p<0.001) respectively 
 
Table No. 22: Effect of hydroalcoholic extract of Plumbago zeylanica L. on SOD 
(U/mg protein) in FCA induced arthritis in female wistar rats. 
 
Treatment SOD  (U/mg of protein) 
Healthy Control 11.23±0.35 
Arthritic Control 2.65±0.34*** 
Indomethacin (10 mg/kg) 9.39±0.56** 
HAEPZ (200 mg/kg) 5.22±0.29*** 
HAEPZ (400 mg/kg) 8.42±0.34*** 
 
Values are expressed as mean±SEM of 6 values 
One way ANOVA followed by Dunnet’s post-test 
**p<0.01, ***p<0.001 when compared to Arthritic Control 
 
Results 
 
79 
 
Histopathology Results 
 
                                          
 
                                        
 
                                                                               
 
 
                                          
 
Fig. 2 
Histopathological 
representation of 
tibio tarsal joint 
of healthy control 
animal. 
Stain: H & E 
Thickness: 5μ 
Magnification: 40x 
 
 
 
Normal 
connective tissue 
of tibio tarsal 
joint. 
No necrosis 
present. 
No lymphocytic 
infiltration 
present. 
Fig. 3  
Histopathological 
representation of 
tibio tarsal joint of 
arthritic control 
animal. 
Stain: H & E 
Thickness: 5μ 
Magnification: 40x 
 
 
 
Inflamed 
connective 
tissue of tibio 
tarsal joint. 
Necrosis 
present. 
Lymphocytic 
infiltration 
present. 
Normal 
connective tissue 
of tibio tarsal 
joint. 
No necrosis 
present. 
No lymphocytic 
infiltration 
present. 
Fig. 4 
Histopathological 
representation of 
tibio tarsal joint 
Indomethacin (10 
mg/kg) treated 
animal. 
Stain: H & E 
Thickness: 5μ 
Magnification: 40x 
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The histopathological evaluation of the tibio tarsal joint show prominent 
inflamed degenerative connective tissue associated with cellular inflammation edema, 
granuloma formation in the vehicle treated animal.  However these changes were not 
observed in the animal treated with Indomethacin (10 mg/Kg). Mild histopathological 
changes were observed in HAEPZ (200 mg/kg) and no histopathological changes 
were observed in HAEPZ (400 mg/kg) treatment groups respectively. However bone 
disruption erosion deformation was not observed.  
 
Inflamed 
connective 
tissue of tibio 
tarsal joint. 
Mild necrosis 
present.  
Mild 
lymphocytic 
infiltration 
present. 
Normal 
connective 
tissue of tibio 
tarsal joint. 
No necrosis 
present.  
No lymphocytic 
infiltration 
present. 
Fig. 5  
Histopathological 
representation of 
tibio tarsal joint 
HAEPZ (200 
mg/kg) treated 
animal. 
Stain: H & E 
Thickness: 5μ 
Magnification: 40x 
 
 
 
Fig. 6 
Histopathological 
representation of 
tibio tarsal joint 
HAEPZ (400 
mg/kg) treated 
animal. 
Stain: H & E 
Thickness: 5μ 
Magnification: 40x 
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DISCUSSION 
 
 
Plumbago zeylanica L.  is an Indian garden shrub with potent medicinal 
properties. The present investigation is undertaken to find its analgesic, anti-
inflammatory and anti-arthritic activity of hydroalcoholic extract of Plumbago 
zeylanica L.              
 
The anti-inflammatory activity was performed using carrageenan induced rat 
paw edema. Carrageenan is a sea weed which serves as a phlogistic substance when 
injected locally into the sub-plantar region. The acute severe inflammation is 
morphologically visible which is evaluated by paw volume. The paw edema induced 
by sub-plantar injection is biphasic. The early phase involves the release of serotonin, 
histamine and kinins, while the late phase is mediated by prostaglandins (77) Vinegar 
et al., 1969). In the present investigation there was an increase in the paw volume 
upon injection of carrageenan as observed at 1h, 2h, 3h,4h and 24h. Pre-treatment 
with hydroalcoholic extract of Plumbago zeylanica L.  200 and 400 mg/kg decrease 
the paw volume at 3h and 4h. Histamine is released at 1h. Serotonin and bradykinin 
are released at 2h and prostaglandins are released at 3h. Thus the observed decrease in 
paw volume might be due to inhibition of prostaglandins. 
           
Insertion of cotton pellet forms granuloma which is a sub-acute inflammatory 
condition. This leads to tissue proliferation and granuloma formation. This method is 
widely employed to assess transudative, exudative and proliferative components. The 
dry weight of the granuloma correlates with the amount of granulomatous tissue 
formed. In the present study dry weight granuloma has significantly reduced with 
HAEPZ 200 and 400 mg/kg treated groups which indicate that HAEPZ at higher 
doses is effective in alleviating inflammation. 
           
Hot plate and tail flick is used to evaluate centrally acting analgesics. In the 
present study there was no significant change brought about by HAEPZ in any of 
these models which indicate HAEPZ is devoid of central analgesic activity. 
            
Discussion 
 
   
 
82 
Formalin is a phlogistic substance which creates localized inflammation and 
hyperalgesia when injected in the sub-plantar region. It shows a biphasic response due 
to neurogenic inflammation (neurogenic pain) followed by participation of kinins, 
leukotriene and prostaglandins. The first phase (0-5 min) is the neurogenic phase 
during which the peripheral nociceptors are stimulated acts on chemoreceptor in the 
nociceptor neuron leading to acute phase. The second phase lasts from 20-30 min 
which represents the inflammatory phase mediated by kinin, leukotrienes and 
prostaglandins. In the present investigation, HAEPZ inhibited the second phase in a 
dose dependent manner but was ineffective in amelioration of the pain in the first 
phase which indicate that HAEPZ does not have inhibitory effect on the release of 
substance P from dorsal root ganglia which is the primary site of central pain. 
However the ability of HAEPZ to inhibit the second phase indicate inhibitory effect 
of HAEPZ on COX pathway. 
          
 Acetic acid is a phlogistic substance which causes localized inflammatory 
response manifested as writhing when injected intra-peritoneally into mice. This is a 
sensitive method for screening peripherally acting analgesic compounds. Acetic acid 
causes release of mediators of inflammation like bradykinin, serotonin, PGE2 and 
PGE2α in the peritoneal fluid which reduce the pain threshold and induces a state of 
hyperalgesia. In the present investigation HAEPZ inhibited the acetic acid induced 
writhing in a dose dependent manner. 
         
The peripheral analgesic activity of acetic acid may be because of inhibition of 
inflammatory mediators which is evident through acetic acid induced writhing and 
formalin induced hyperalgesia models. The ability of HAEPZ to inhibit the COX 
pathway is also established through carrageenan induced paw edema model. 
          
FCA induced arthritis is a well established model which mimics human 
pathological state. This model was pioneered by Pearson and Wood (1963). FCA 
comprises of heat killed Mycobacterium tuberculi suspended in paraffin oil. This is a 
widely used animal model which represents chronic immune mediated joint 
inflammation that is induced by intradermal or subcutaneous injection of FCA. 
Ensuing polyarthritis represents a localised inflammatory and systemic disease. 
Symptoms are visible not only in the injected paw but in ankle, wrist, tarsal, carpal 
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and inter-phalangeal joint.  FCA arthritis follows a biphasic time course consisting of 
an acute inflammatory condition which peaks at 3 to 5 days and a chronic systemic 
reaction that shows a relaxing remitting course persisting for several weeks (78) 
Schaible et al., 2001 , (79) Bendele 2001 , (80) Seino et al., 2006). The 
immunologically mediated FCA arthritic model of chronic inflammation is considered 
as the best experimental model of rheumatoid arthritis (81) Williams 1998). The 
bacterial peptide glycan and muramyl dipeptide and important nonspecific 
immunogenic components (82) Crofford and Wilder, 1993) Adjuvant arthritis with 
or without an autoimmune component induced by compound which does not contain 
MHC binding peptide but involves T cell activation intra-dermal or subcutaneous 
injection of Freund’s adjuvant produce a chronic relapsing arthritis with 
characteristics of rheumatoid arthritis . In this model immunologically mediated 
chronic synovial inflammation and macrophage play a central role. After activation 
they are capable of synthesising mediator such as PGE2 and cytokinin such as TNFα 
and Intelukin–1. In turn their synthetic product induce the production of variety of 
enzymes which initiate cartilage and bone destruction (83) Hopkins, 1990, (84) Jadot 
et al., 1986). In the chronic inflammation, activated immune system can release a 
series of pro-inflammatory mediators cytokinin, including tumour necrosis factor 
(TNF α).  
         
Several cytokines (TNF α IL-1, IL-6, and GM-CSF) and activated β cells and 
T cells play a crucial role in RA joint inflammation. The persistence of inflammation 
in established RA is driven by interaction between T cells, macrophages and 
fibroblasts in an abnormal microenvironment. The synovial T cell population is 
maintained through active inhibition of apoptosis, mediated at least in part by 
fibroblast and macrophage derived type 1 TNFs and active retention facilitated by 
fibroblast derived transforming growth factor β. Contact dependent interaction 
between T cell and macrophages stimulate the production of pro-inflammatory 
cytokinins including TNFα in an antigen independent manner . Cytokines secreting T 
cells may indeed play a role in an inflammatory synovitis both by initiating and 
maintaining the disease process (85) Raza et al., 2005). Progression of RA is 
associated with an imbalance of Th1/Th2 and overproduction of antigen specific 
immunoglobulin (86) Panayi, 1997). 
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These inflammatory mediators produce profound changes in the injected paw 
which can be  evaluated using various parameters like change in paw volume ,change 
in joint diameter, WBC count, pain threshold (in grams in randall sellito), arthritis 
score, paw withdrawal tendency,  serum albumin, serum acid phosphate, oxidative 
stress in liver due to arthritis, paw weight, and histopathology. In the present 
investigation the change in paw volume during the entire treatment period was 
monitored and percentage inhibition was determined at various time points in all the 
treatment group of animals. The rise in paw volume was inhibited in dose dependent 
manner proving the ability of HAEPZ to inhibit the inflammatory, oxidative changes 
which occur in FCA induced arthritis. Synovitis of the tibio tarsal joint was inhibited 
in the animals treated with HAEPZ depicting the ability of HAEPZ to inhibit immune 
mediated joint inflammation and synovial hyperalgesia and accumulation of 
neuterophil. The joint diameter of the HAEPZ treated animals was not elevated when 
compared with the vehicle treated control group animals.  
 
FCA induced arthritis leads to peripheral pain and hyperalgesia. The neurons 
in the injected paw become sensitive to allodynia and hyperalgesia induced by 
nociceptive agents which are measured using randall sellito. Rats with severe arthritis 
in the vehicle treated group demonstrated low paw withdrawal threshold. The animals 
treated with HAEPZ are able to bear significantly higher pressure while subjected to 
Randall Sellito analgesiometer whereas the animals in the control group were able to 
bear the pressure demonstrated as a very small latency and minimum weight bearing 
capacity due to severe arthritic condition. Randall sellito throws light on the weight 
bearing hyperalgesic response. In the present investigation HAEPZ was able to 
alleviate both the pain responses in the plantar region of the rats in various treatment 
groups. 
 
Thermal hyperalgesia is an important parameter used to evaluate the disease 
condition in FCA induced arthritic rats. In arthritic condition the thermo receptors 
located at the injected paw are stimulated at a lower threshold than normal animal or 
the non-injected paw. Hence the paw withdrawal latency in the ipsilateral paw of the 
animals treated with HAEPZ at all the three doses showed prolong latency period 
when compared with the vehicle control group of animals .These investigations are in 
accordance with the study done using acetic acid as the phlogistic substance leading 
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to nociceptive condition. Hence the anti-inflammatory and peripheral analgesic 
property of HAEPZ is well explained via a plethora of in-vivo tests. 
 
The WBC count in the synovial fluid and the circulating blood is elevated in 
inflammatory condition of the total WBCs count was elevated in the control group 
whereas in the HAEPZ treated group the elevation of WBC count was inhibited. This 
provides credence to the fact that HAEPZ is able to not only to reduce the 
inflammatory condition at the systemic circulation. 
 
Paw weight corresponds to the accumulation of exudate in the injected paw 
leading to elevation of weight. The various inflammatory mediators cause 
accumulation of lymphocytes, macrophages and other inflammatory mediators at the 
site of injection leading to increase in the weight of the paw. In the present 
investigation the elevation of paw weight was found to be inhibited in the HAEPZ 
treated group in a dose dependent pattern which further supports the anti-
inflammatory profile of HAEPZ. 
 
Histopathological studies also show severe exudative changes and infiltration 
of nuetrophils and macrophages in the inflamed tissue when section 0f 5μ was made 
and stained with hematoxylene and eosin. However these changes were absent in the 
HAEPZ 200mg/kg and indomethacin treated animals.  
 
RA is not only restricted to paw but it is also systemic disease which affects 
the overall oxidative stress in the animal. This fact is an indispensable and inevitable 
factor which needs to be thoroughly investigated. The oxidative stress is visible in the 
synovial tissue and liver of the arthritic animal. The serum levels of ACP, Albium, 
ALP are elevated in arthritic animals. In the present investigation HAEPZ was able to 
venture the elevated and reduced level of ACP, ALP and albumin in the animals 
treated with HAEPZ in a dose dependent manner. Serum alkaline phosphatase and 
acid phosphtase was significantly increased in the control group of animals. However 
the elevated levels of ACP and ALP were reduced in the animals treated with HAEPZ 
in a dose dependent manner. 
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Oxidative  stress plugs a pivoted role  in modulating the disease state in 
arthritis FCA induced arthritic model demonstrates a severe rise in the various 
cytotoxic free radicals in plasma joint as well as liver (87) cerhan et al., 2003 , (88) 
Rajkapoor et al., 2009). In adjuvant induced arthritis lipid peroxidation leads to 
tissue damages and is associated with the aggravation of arthritis (89) Halliwell et 
al.,1988). Lipid  peroxidation causes lysosomal destruction which also evolves in 
arthritis development hence the level of these enzymes in the liver serves as the 
representation of the  oxidative stress in the entire body of the animal. Hence SOD, 
GSH and MDA were measured in the liver of the rats in the various treatment groups. 
Glutathione is endogenously synthesized in the liver and serves as first line of defense 
against oxidative stress and peroxidation (90) Rasool and Varalakshmi, 2009).                                  
 
The role of NO has been well established in an anti-inflammatory response. 
As the inflammatory response progresses, large quantities of NO are generated 
through the induction of iNOS (inducible Nitric oxide synthase ) that reacts with 
superoxide anion to form peroxynitrate a potent oxidizing molecule capable of 
eliciting lipid peroxidation. Lipid peroxidation is the oxidative deterioration of 
polyunsaturated lipids to form radical intermediates that bring about cellular damage. 
MDA, a major end product of this reaction, is an index of lipid peroxidation and has 
been estimated as TBARS besides, the infiltrating cells also generate reactive oxygen 
species and free radicals that brings about destruction of the inflamed joint. As a 
result, the scavenging enzyme SOD that leads to the formation of hydrogen peroxide 
is utilized and its activity is reduced in arthritic rats. The hydrogen peroxide thus 
generated is decomposed by catalase and glutathione peroxidase. Excessive 
production of lipid hydrogen peroxide may also contribute to decreased activity of 
GPx in arthritic condition. Beside enzymatic antioxidants, the level of glutathione, a 
non-enzymatic reducing agent that traps free radicals and prevents oxidative stress, is 
also decreased in arthritis. The most reactive oxygen species in biological system are 
superoxide anion, hydroxyl radical and hydrogen peroxide (91) Badgujar et al., 
2009). Superoxide dismutase can change superoxide anion radical to hydrogen 
peroxide and catalase cleaves this hydrogen peroxide into the molecules of water and 
oxygen. Glutathione  peroxidase is also a detoxifying enzyme, changing the peroxides 
to water (92) Lawrence and burk, 1976). In the CFA reagent induced rheumatoidal 
model, the increase of lipid peroxide could be attributed not only to the activation of 
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xanthine  oxidase and aldelyde oxidase but also to the deactivation of superoxide 
dismutase, catalase and selenium-dependent glutathione  peroxidase. In the present 
investigation, the level of oxidative stress markers in the liver was determined at the 
end of the study. HAEPZ was able to inhibit the oxidative changes brought about by 
FCA. The elevated MDA levels in the control groups were reduced where as the 
reduced SOD and GSH levels were elevated to restore normal level of oxidative 
markers in the livers. This response was dose dependent. It could be postulated that 
the amelioration of arthritis was due to the suppression of oxidative stress in the liver 
of the animals. It is to be noted that Plumbago zeylanica L.  has been proven to 
ameliorate myocaradial ischemic reperfusion injury by inhibiting lipid peroxide SOD, 
catalase and glutathione. 
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CONCLUSION 
 
It could be concluded from present investigation that HAEPZ possesses potent 
anti-inflammatory, peripheral analgesic and anti-arthritic property. It was able to 
inhibit acute inflammatory response in various animal models & was able to 
ameliorate arthritic changes in the FCA induced RA model in rats. It also exhibited a 
potent antioxidant profile by inhibition of generation of ROS and decrease in 
oxidative stress. These observations provide pharmacological credence to 
ethnobotanical claims of traditional Indian system of medicine. This study proves for 
the first time anti-arthritic potential of HAEPZ. The study would contribute to 
develop novel herbal formulations which will pave the way for explorations of novel 
vistas in the field of anti-inflammatory drugs. 
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